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ABSTRACT 
  
 The pathology of multiple sclerosis (MS) is characterized by an inflammatory 
mononuclear infiltration in the white matter. There has been converging evidence of the 
oxidative stress playing a role in the onset and progression of MS. We postulated that 
the decreasing oxidative stress might help in the management of MS. We know that the 
induction of phase 2 enzymes decreases the oxidative stress. The experimental allergic 
encephalomyelitis (EAE) induced in the Lewis rats were used to test this hypothesis. 
The 24 animals were placed into two groups: 1) those on normal rat chow, 2) those on 
rat chow containing 7.5 g/kg of tetra-butylhydroxyanisole (BHA), a food preservative. All 
the animals were administered 100 µg of guinea pig myelin basic protein in their tails to 
induce EAE and examined daily in a double blinded fashion. On 29th day of the 
induction, the animals were sacrificed, blood collected for glutathione (GSH) 
measurements and tissues collected for histology. All the animals, regardless of their 
diet status, developed symptoms of EAE on different days ranging from tail weakness to 
hind limb paralysis and all of them reached remission of acute EAE before the 28th day 
of induction. The  non-BHA fed animals developed hind limb weakness  in 8 animals 
and  hind limb paralysis in 4 cases, while that of BHA fed group developed tail paralysis 
in 2, hind limb weakness in 2 and hind limb paralysis in 8 cases. The histology of the 
non-BHA group correlated well with the clinical symptoms of perivascular mononuclear 
infiltration. However, the BHA group revealed complete pathological recovery. Animals 
with BHA in the diet had significantly raised GSH, indicating the induction of phase 2 
enzymes. We conclude that dietary phase 2 enzyme inducers show potential 
therapeutic benefits in EAE and should be examined for this role in MS. 
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1.0 REVIEW OF THE LITERATURE 
1.1 Introduction 
Multiple Sclerosis (MS) is still the major disabling neurological disease in young 
adults, affecting 0.05-0.15% of the Caucasian population. It usually starts in young 
adulthood with a clinical bout encompassing symptoms like visual disturbances, 
numbness and/or tingling, difficulties in walking or coordination, and sometimes 
unspecific complaints, like fatigue, attention, or endurance problems [1]. Possible causes 
of this disease are viral and/or autoimmune in nature. MS is influenced by genetic and 
environmental factors, but the root cause of the disease remains unknown. The 
distinguishing features of MS include demyelination zones with T-cell, predominantly 
perivascular, inflammation in the white matter of the spinal cord and brain. These 
features may not impact all axons.  MS is relatively benign in a majority of patients and 
is marked by a few attacks which become increasingly worse and more common with 
time. This stage of the disease is known as relapse-remitting MS (RRMS). 
Subsequently, one is never able to acquire complete functionality again upon remission 
of the disease, with disability occurring in later stages. This last stage is known as 
secondary progressive MS (SPMS) [2-3]. 
MS does not necessarily exhibit the same series of events in all patients. Primary 
progressive MS is more common among females. Furthermore, the axons are less 
damaged than in SPMS [4]. The disease also does not make a transition from one stage 
to the next as RRMS does prior to SPMS [3]. Consequently, primary progressive multiple 
sclerosis (PPMS) can seem distinct in its development. There are MS variants that 
progress quickly, including acute or Marburg's MS, neruomyelitis optica (Devic's 
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disease), and Balo's concentric sclerosis.  Benign disease patterns or those 
characterized by single attacks can also be diagnosed as MS [3, 5]. 
One study that includes biopsy and autopsy analyses conducted 
primarily by a multicenter collaborative group show a heterogeneous 
pathology behind clinical MS. Four pathologies can be identified based on 
what has been learnt so far [6]. Two immune-inflammatory pathologies which 
demonstrate focal, perivascular lesions of T-cells and macrophages (Type I), 
and antibody and complement (Type II), are the most common of the four 
pathologies. The lesions are due to demyelination and damage of axons in 
the white matter. Rarer pathologies include those that exhibit damage caused 
by viruses or toxins, or those that are the result of ischemia with diffuse 
white matter involvement (Type III), and what seems to be primary 
oligodendrocyte dystrophy (Type IV) [6-7]. More analysis is needed to 
determine whether these pathologies can occur simultaneously in the same 
patient [8-9]. From these studies, one can conclude that the pathology of MS is 
quite heterogeneous. Other studies have demonstrated that pathology in 
some MS variants include more characteristic features than the classical 
demyelinated plaque in white matter. Demyelinated plaque is a consequence 
of acute and RRMS. Chronic disease, on the other hand, is marked by 
cortical involvement, greater microglial activation, and diffuse myelin and 
axonal loss [10-11]. Acute MS commonly does not exhibit intrathecal 
immunoglobulin synthesis or oligoclonal immunoglobulin bands in 
cerebrospinal fluid (CSF). These features are hallmarks of MS and were used 
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for diagnosing the disease before the advent of MRIs. Several cases of 
SPMS show less immune involvement than other forms of MS, such as 
decreased T-lymphocyte infiltration. However, activated macrophages or 
microglia is present throughout [3]. The graphic representation of possible 
pathology is in fig.1.1 
 
Fig. 1.1: MS Pathology (Courtesy: JCI [12]) 
Working hypothesis as to the cause of MS. (I) In a genetically susceptible host, common microbes both activate the 
APCs through toll receptors and contain protein sequences cross-reactive with self myelin antigens. This leads to 
what can be defined as the minimal requirement for inducing an autoimmune, inflammatory CNS disease in 
mammals. (II) Underlying immunoregulatory defects, such as decreases of regulatory T-cells in the circulation of 
patients with MS, allow the further pathologic activation of autoreactive T-cells (96). (III) Activated myelin-reactive T 
cells migrate into the CNS and recognize antigen presented by microglia, local APCs. Th1 cytokines are secreted and 
an inflammatory cascade is initiated. (IV) Regulation of autoimmune responses. Naturally occurring mechanisms may 
exist to regulate autoimmune responses including the induction of autoreactive Th2 (IL-4, IL-5, IL-13), Th3 (TGF-β), 
or Tr1 (IL-10) cytokine–secreting T-cells that migrate to the CNS and downregulate (red arrow) inflammatory Th1 
autoreactive T cells (green arrow). Therapies may attempt to induce Th2 (Copaxone, altered peptide ligands), Th3 
(mucosal antigen), or Tr1 (β-IFNs, steroids). ThP, precursor T-cell. 
  
 
4 
 
The roles of cytokines in MS pathology are very important. However, there have 
been various studies that sometimes contain conflicting expressions of different 
cytokines. The cytokines that are generally found to be increased during the disease 
process are TNF-α, sTNFRI, LT, IFN-γ, IL2, sIL2R, IL6, IL23, Osteopontin, and Oncostatin 
M [13-18]. The cytokines that are generally decreased during the disease process are IL4, 
IL10, IL12, TGFβ, IL12p40, IL13, IL15, IL18, and IL17 [19-21]. In conclusion, the polymorphism in 
the expression of various cytokines at different stages or clinical setups of MS makes 
the well demarcated association difficult at all the times. The complicated interactions of 
the various cytokines are graphically expressed in fig. 1.2 [22]. 
Oxidative stress has been blamed in numerous pathologies including MS [23-27]. 
The role of oxidative stress and effectiveness of antioxidants of various kinds have been 
studied in various demyelinating conditions of the brain. It has been established in 
animal models like experimental allergic encephalomyelitis (EAE), an excellent model 
for multiple sclerosis (MS), especially expressing the possible autoimmune 
pathogenesis of MS. 
 The possibly predominant role of oxidative stress in the pathogenesis of multiple 
sclerosis has been considered as a target for therapeutic intervention. Various efforts 
have been made at the experimental animal levels using different chemical antioxidants. 
We would like to exploit the same pathway using the dietary antioxidant tetra-
butylhydroxyanisole (BHA), commonly used in food preservation, in our EAE models.  
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Fig. 1.2: Cytokines control mechanisms of structural damage to myelin and axons. Immune cells (CD4, CD8, T- 
cells, and B lymphocytes) are directed by chemokines to encounter APC (microglia or DC), which present their 
cognate autoantigen for reactivation. Pro-inflammatory cytokines (e.g. IFN-γ, IL23, osteopontin OPN) are secreted 
by T-cells and either directly affect myelin structures or activate macrophages to release nitric oxide (NO), 
reactive oxygen intermediates (ROI), matrix metalloproteinases (MMP), or TNF-α. CD8 cells may directly attack 
axons by release of the cytotoxic mediator perform (PFN). B lymphocytes are induced to terminal plasma cell 
differentiation by Th2 cytokines, and upon activation release myelin-specific antibodies, which can induce 
complement (C) mediated demyelination. Plasma cell Macrophages factor in the blood, CSF, or destructive lesion 
of MS patients could be a hint for a causal relationship, but it could also represent an endogenous regulatory 
process to reduce tissue damage or indicate an innocent epiphenomenon. Considering these three options, any 
therapeutic approach counteracting a specific factor may result in different outcomes depending on its temporal 
and spatial role during inflammation or tissue destruction. These problems are best exemplified by the story of 
TNF-α in MS. 
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The various beneficial pathways of dietary antioxidants are expressed in fig. 1.3. 
 
Fig. 1.3: Beneficial pathways of dietary antioxidants {Model for metabolic biology and chemopreventive activities of 
phenolic antioxidants. (Adopted with courtesy from Brash and Have, PNAS 2002; 99, 13969)} 
 
1.1.1 Historical Perspective 
The first case of MS was found in 1824 in a young man as myelitis [28]. MS cases 
came to be known as sclerose en plaque dissemine, a name that Vulpian christened to 
the disease in 1866 [29]. The name, disseminated sclerosis, was subsequently replaced 
by multiple sclerosis which was obtained from its German name [30].  
It was in the 19th century that the pathologic characteristics of MS were studied. 
In 1838 [31] and 1841 [32] respectively, Carswell and Cruveilier described the 
morphological characteristic in MS patients: sharply circumscribed translucent gray 
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sclerotic plaques in the CNS white matter. Rindficisch in 1863 and Charcot in 1868 
described the microscopic attributes of the MS plaque including perivascular 
inflammation which occurred due to demyelination, axonal damage, and astrocytic scar 
formation [33-35].  The laboratory markers of the disease were determined in 1948 by 
Kabat [36-37]. These included an increase in oligoclonal immunoglobulin in the 
cerebrospinal fluid (CSF) of MS patients [12, 38]. Between 1999 and 2001, Lucchinetti et 
al. delineated the structural and immunopathological subtypes of MS [39-40]. 
Interindividual heterogeneity and intraindividual homogeneity was found in terms of the 
immunological basis of demyelination, what happens to oligodendrocytes, and the 
range of axonal damage and/or remyelination.   
1.1.2 Epidemiology 
One million people are impacted by MS globally. North America is witness to 
350,000 cases. The ratio of women to men affected by MS is 2:1. MS generally strikes 
patients in young adulthood and is characterized by frequent inflammatory attacks 
against the white matter of the spinal cord and brain. Blindness, loss of sensation, lack 
of coordination, loss of bowel and bladder control, and difficulty in walking are all 
features of MS. MS pathology is characterized by a plaque which is a region of myelin 
that has been exposed due to inflammation and scarring by a non-neuronal cell in the 
brain, such as microglia that are derived from BM, and the star-shaped astroglia which 
are derived from the brain. The specific cause remains unclear. Two theories have been 
postulated to explain why this happens: either it is due to an autoimmune reaction (post-
inflammatory) or a neurodegenerative process followed by inflammatory response (pre-
inflammatory). 
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Europeans or the descendants of European ancestors make up the majority of 
patients affected by MS [41]. MS is quite rare in certain races and is well-studied [42]. 
Such groups include American Indians, African blacks, Hutterites [43], and Asians. 
Demyelinating diseases are also found in Asians but their pattern and laboratory results 
are different from those of MS [44-45]. The world-wide distribution of MS is described in 
fig. 1.4. 
 
Fig. 1.4: The world-wide distribution of MS 
 
1.1.3 Genetics of MS 
The role played by genes and the environment in the etiology, susceptibility, 
onset and prognosis of MS needs to be clearly outlined.  
It was in the 1800s when Gowers [46] declared that occurrence of MS within 
families was extraordinary and Eichhorst described MS as an "inherited, transmissible" 
disease [47]. From 1921-1948, medical literature described a total of 64 sibling pairs, 13 
parent-child pairs, and 15 second and/or third-degree relative pairs as having MS [48]. 
These were single case reports as opposed to large series. Research on familial MS 
was impeded by the lack of consensus diagnostic criteria until 1965 [49], which have 
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been updated to include technological advances and understanding about the natural 
history and heterogeneity of the disease [50-51].  
“Multiplex families” was a name given to families with greater than one case of MS, 
had hereditary cerebello-pyramidal disease or hereditary spastic ataxia [52-53]. One of 
these types of families with 12 affected patients [54] actually had the Pelizaeus-
Merzbacher disease [55] instead of MS. Irrespective of this, multiplex, multigenerational 
MS families do exist and the evidence for this is quite substantial [56]. It is unknown 
whether these families exhibit a rare, autosomal dominant form of MS which was found in 
5% of cases of Alzheimer’s disease [57] and which had been hypothesized for MS several 
years ago [58].  
1.1.4 MS Susceptibility and Genes 
The HLA class I antigens A3 and B7 [59-61] were the first genetics links to MS. These 
were later subtyped into a strong and consistent link with the HLA DR15, DQ6, and Dw2 
haplotype [62-65]. Recent research has cast doubts as to whether this link truly is as 
simplistic as described here [66-67].  
In the search to determine a genetic link to MS, association studies, 
whole genome scans, SNP analyses, HapMap approaches and a variety of 
other experiments have been conducted but to no avail. To date, no specific 
gene has been identified for MS. The University of California in San Francisco 
has an in-depth listing of the MS candidates (positive and negative) [68]. Our 
inability to identify the genes responsible for MS can be thought of as an 
indicator of the disease’s intricacy instead of assuming that a genetic link is to 
blame. Other disease such as diabetes and Alzheimer’s disease also exhibit a 
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difficulty in determining a genetic link. These diseases, along with MS, are 
known as common complex disorders.  
Longitudinal, population-based, genetic epidemiological studies are used to 
identify the relative roles of genes and environment in MS. 
1.1.5 Familial Recurrence Risks 
Employing the classical genetic epidemiological approach meant that the initial 
step was to determine whether relatives of MS patients were at a higher risk of coming 
down with the disease compared to the rest of the population. The Canadian Network of 
Multiple Sclerosis Clinics [69] allows one to study age-adjusted familial recurrence risks 
with first-degree relatives of MS patients and compare them to the rest of the 
population. The age-correction methodology adopted in these studies has been verified 
by the Vancouver Multiple Sclerosis Clinic which first stated these risks [70] and by the 
longitudinal follow-up of Canadian MS patients [71]. Additional studies coupled with these 
Canadian studies [72-74] have shown that first-degree relatives of MS patients are at 
greater risk of developing MS.  
This is due to the biological sharing of DNA rather than a common family 
environment which promotes the increased frequency of MS within biologically related 
family members [75-78].  
Majority of the individuals affected with MS are females. Evidence has been 
mounting, however, that there may be a parent-of-origin effect in MS whereby a 
maternal effect may be at work [76-77, 79].  
A recent study of four northern MS populations [80] discovered a May:November 
birth ratio in living MS patients from Scotland (1.89), Denmark (1.22), Sweden (1.18), 
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and Canada (1.13). This means that there is a peak in May and a nadir in November. 
Intriguingly, the birth month ratios declined in the order of the prevalence of the 
population. A potential parent-of-origin effect is seen with this data. Furthermore, one 
can compare this data with earlier observations of links between higher latitudes and 
risk of MS. This suggests that sun exposure may be the reason for the geographical 
variation of MS [81-82]. Exposure to ultraviolet radiation produces most biologically active 
vitamin D [82]. The ascending risk of MS in relation to the birth month may be due to 
seasonal shortage of vitamin D in the mother [83]. Vitamin D receptors are found in the 
brain, as recent literature shows, and the gestational shortage of vitamin D has a major 
impact on brain development in experimental animals [84].  
The precise impact of genes and the environment on MS is still unclear. The 
indisputable facts up until now include the following, however:  
¾ MS is the product of an interaction between genes and the environment. 
¾ The sharing of genetic material is the cause for the phenomenon of 
increased frequency of MS within families compared to the general 
population.  
¾ The environmental impact of MS acts at the population level as opposed to 
in the family environment.  
¾ Transmission of susceptibility to the disease is variable based on several 
factors such as the gender and age at which the disease developed in 
family members.   
¾ Several genes are at work here. Therefore, etiologic heterogeneity is a 
possibility. The link between MS and MHC may be more complicated than 
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it seems.  
¾ MS can not be transmitted at any point in an individual's lifetime.  
The information from genetic epidemiological studies is being used in genetic 
and reproductive counseling for MS families. This shows how research and clinical 
practice can be linked.  
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1.2 Pathology of MS  
1.2.1 Demyelination 
MS is a dynamic disease and is marked by several levels of demyelination. The 
MS plaque may show the different levels of demyelination such as early and late active 
demyelination along with completely demyelinated regions that may or may not be 
remyelinated, in one lesion. The non-remyelinating regions are inactive areas. Actively 
demyelinating lesions, on the other hand, are characterized by a variable inflammatory 
infiltrate comprised primarily of macrophages, reactive astrocytes, and different 
lymphocytic cuffs. Different immunocytochemical stains can be used to identify the 
different levels of demyelination [80, 85]. These include antibodies to minor myelin 
proteins, such as myelin-associated glycoprotein (MAG) and myelin oligodendrocyte 
glycoprotein (MOG). Antibodies to major myelin proteins such as myelin basic protein 
(MBP) and phospholipid protein (PLP) along with the Luxol fast blue (LFB) myelin stain 
are also other examples of immunocytochemical stains that can be used to demarcate 
the level of demyelination. The early active demyelinating lesion is defined by reactive 
astrocytes and macrophages carrying granules that are positive for LFB and which 
contain both minor and major myelin proteins. Due to the quick degradation of minor 
myelin proteins, macrophages in the late active lesions only carry the more slowly 
digested major myelin proteins, namely, PLP and MBP. Due to their declining activity, 
these PAS-positive, granule-carrying macrophages begin to aggregate in large numbers 
to perivascular areas instead of being interspersed throughout the lesion. In the later 
levels of demyelination, macrophages do not have any more myelin peptides or partially 
digested glycoproteins which means that the granules are neither LFB- nor PAS-
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positive. Inflammation subsequently decreases. However, glial reactivity remains. 
Hypocellularity defines the inactive, chronic MS lesion, which only carries astrocytes 
and has scattered perivascular chronic infiltrate. The general pathological process in MS 
is expressed below in Fig. 1.5.  
 
 
 
 
Fig. 1.5: A pathological representation of the disease process. Cross-reactive viral antigen or CNS antigen is 
processed in peripheral lymph nodes and presented to lymphocytes resulting in their clonal expansion, release and 
migration into the CNS where they are reactivated upon recognition of the myelin bound antigen. CD8+ T-cells 
interact directly with oligodendrocytes and neurons inducing apoptosis. CD4+ T-cells recognize antigen presented by 
CNS resident microglia and secrete cytokines required for maintenance of the inflammatory environment. These 
cytokines induce MHC expression on CNS resident cells, disrupt the blood brain barrier to allow further cellular 
infiltration, and attract peripheral macrophages, further enhancing the immune response. 
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In early active MS lesions, there are four histopathological patterns of 
demyelination. The factors involved in distinguishing these patterns include plaque 
geography, extent of oligodendrocyte survival, levels of remyelination, presence of 
complement activation, and loss of myelin proteins [86]. When a biopsy and autopsy was 
performed on 82 patients with early MS, about 70% of the lesions had demyelinating 
patterns with primary myelin destruction which described patterns I and II. Both of these 
patterns showed sharp macrophage borders on the plaque edge and the surrounding 
periplaque white matter (PPWM). Furthermore, perivascular myelin loss and infiltration 
by macrophages and CD8 T-lymphocytes were also evident. Immunoglobulin and 
complement deposition within macrophages and at sites of active myelin destruction are 
found only in pattern II lesions. A primary oligodendrocyte (OLG) injury is found in the 
last 30% of MS cases and this is characteristic of patterns III and IV. Pattern III lesions 
are marked by a great deal of macrophage and T-cell infiltration but have poorly defined 
macrophage rims, perivascular sparring of myelin, absence of complement activation, 
and a loss of myelin associated glycoprotein (MAG) on the plaque edge, along with 
prevalent OLG apoptosis with little remyelination. Pattern IV lesions show degeneration 
of oligodendrocytes in the normal-appearing periplaque white matter (PPWM), no MAG 
loss and no complement activation [86-87]. After analyzing several active lesions at 
autopsy or of several biopsies of the same patient, it has been demonstrated that the 
immunopathological pattern has remained consistent. Interindividual heterogeneity 
implies that the targets and immunopathogenic mechanisms which lead to tissue injury 
in MS may be heterogeneous [86].  
The cellular make-up of tissue damage and repair found in MS lesions is 
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heterogeneous among MS patients. Oligodendrocytes within MS plaques are prone to 
injury by several immune and toxic agents. For example, both myelin and 
oligodendrocytes can be injured by tumor necrosis factor alpha (TNF-α) or interferon 
gamma (IFN-γ), reactive oxygen and nitrogen species, T-cell products (i.e., perforin or 
lymphotoxin) and CD8 cytotoxicity, and other inflammatory products.  Other examples of 
toxins that can cause harm within MS plaques are excitatory amino acids (i.e., 
glutamate), complement cascade proteins, proteolytic and lipolytic enzymes, or viral 
infections [88-89].  
Dysregulation of T-lymphocyte and/or oligodendrocyte apoptosis, namely the 
Fas-Fas ligand pro- and bcl2 anti-apoptosis cascades, were all implicated in the MS 
pathogenesis. These stimuli may lead to different degrees of demyelination, 
oligodendrocyte loss, or axonal injury in MS plaques. 
Demyelinating MS lesions are classified by structure based on oligodendrocyte 
density and extent of remyelination along with how much of the axon is preserved 
relative to the periplaque white matter. About 70% of MS patients have plaques with 
preserved oligodendrocytes and a great deal of remyelination which is known as OLG 
category I lesions. The oligodendrocytes in these MS plaques are present because they 
either survived the injury from the demyelination or were taken from OLG progenitor 
pools after the acute phase of demyelination [89-90]. The last one-third of MS patients has 
OLG category II lesions which have decreased oligodendrocyte survival and little or no 
remyelination. The density of macrophages, CD8 (cytotoxic) T-cells, and density of 
oligodendrocytes in MS lesions at all levels show a major negative correlation. This 
inverse correlation suggests that macrophages and cytotoxic T-cells have a very 
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important pathogenic role to play in decreased oligodendrocyte survival and 
remyelination [40]. OLG category I lesions are more commonly linked with patterns I or II, 
but diminished oligodendrocyte preservation (OLG category II lesions) is seen in 
patterns III or IV of active demyelination [87, 91]. Oligodendrocytes are preserved or lost 
differently in acute MS lesions which support the hypothesis of a heterogeneous 
pathology of demyelination and oligodendrocyte damage or preservation in lesions [88-
89].  
The occurrence of remyelination in early MS lesions correlates with 
oligodendrocyte survival. But the narrow range of remyelination in chronic MS lesions is 
not only due to an absence of these cells. Oligodendrocytes may be preserved to 
varying extents in chronic MS plaques with no remyelination [92]. These sources of 
"premyelinating" oligodendrocytes can be used as substrates for remyelination. These 
chronic lesions do not have the necessary pro-remyelinating environment. 
Remyelination needs healthy oligodendrocytes but also intact interactions between the 
axons and oligodendrocytes, growth-promoting cytokine and chemokine profiles, along 
with limited fibrillary gliosis for extending the myelin processes within the MS plaque [87, 
92-95].  
A high level of interindividual heterogeneity is seen within the structure and 
immunopathology of MS lesions [86]. The histopathology of lesions and the clinical 
course and outcomes in prototypic MS show no correlation. Acute, relapse-remitting, 
secondary progressive, primary progressive, or progressive-relapsing courses of MS, all 
fail to correlate with the immunopathological patterns of demyelination. All lesions from 
one patient show only one pattern of demyelination, similar oligodendrocyte density, and 
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degree of remyelination along with comparable degrees of axonal injury [40]. This shows 
that different "mechanisms and targets" of demyelination and tissue destruction and 
repair are behind the pathological subgroups, irrespective of clinical characteristics [86, 
91]. MS therapy can be focused in future on searching for less-invasive clinical or 
paraclinical surrogate markers to accurately distinguish between pathological subtypes 
[86, 89, 91, 96].  
1.2.2 Remyelination 
Remyelination, unlike demyelination, restores structural and functional integrity in 
denuded axons. Clinically, early remyelination, which precedes or prevents more axonal 
damage, is crucial in improving or slowing neurological disability in MS patients. No 
conclusions can be drawn from information on the frequency, course, or extent of 
remyelination in MS lesions, derived either by pathological or radiological methods. 
Remyelination is partially limited by the degree of oligodendrocyte and axon preservation 
after the injury [86]. Intraindividual heterogeneity of MS lesions is stark obvious in terms of 
the character of the inflammatory infiltrates in the early demyelination lesions and in terms 
of oligodendrocyte survival and remyelination at all stages of demyelination [40, 86].  
Remyelination is partially limited by the degree of oligodendrocyte and axon 
preservation. How much remyelination has occurred in MS lesions varies from none to 
partial, which is limited to the lesion edge, and rarely, reaching throughout the whole of the 
previously demyelinated lesion.   
The ultrastructural characteristics of remyelination include shortened internodes 
and decreased myelin thickness to an axonal diameter ratio, relative to the surrounding 
normal-appearing (or periplaque) white matter (NAWM or PPWM) [89, 97-98). Early 
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remyelination is marked by patches of thin, short, and irregularly ordered myelin sheaths 
or groups of preserved (or recruited progenitor) oligodendrocytes as well as short myelin 
processes, mixed in with the macrophage-rich infiltrate [89, 99).  
Macrophages in remyelinating regions within inactive (completely) demyelinated 
plaques lack myelin degradation products, which mean that they are negative for LFB, 
PAS or myelin protein stains. On the contrary, remyelinating lesions have little or no 
inflammation within regions of relatively thin, yet more densely packed and regularly 
organized myelin sheaths that may cover all of the previously-naked axons. These 
sharply demarcated regions of myelin pallor may show widespread fibrillary gliosis and 
axonal loss, relative to the surrounding PPWM (85, 89]. Remyelination can be difficult to 
identify microscopically from active MS lesions with incomplete demyelination. Even 
though both have thin, truncated, and irregularly arranged myelin sheaths, the active 
demyelinating lesion is defined by T-cells and macrophages which contain granules 
bearing myelin degradation products [89].  
Remyelination can also be mistaken for secondary (Wallerian) degeneration. 
Both are defined by areas of myelin loss. However, Wallerian degeneration displays a 
decrease in the axonal number and an absence of T-cell infiltration which is present in 
MS lesions [89]. Active remyelination can also happen in lesions with concurrent 
demyelination which further complicates the process of identifying MS lesions. These 
active demyelinating and remyelinating (ADM/RM) plaques are similar to the typical 
remyelinating MS lesions with T-lymphocytes and macrophages bearing myelin 
degradation products and which also exhibit diverse immunopathological patterns which 
are described in nonremyelinating early active demyelination lesions. Remyelination is 
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more often seen with the early active autoimmune patterns of demyelination (patterns I 
and II) and rarely in patterns III and IV which are normally linked with major 
oligodendrocyte loss [89, 100-101). 
1.2.3 Pathology of Axons 
Oligodendrocytes wrap around approximately 40 adjacent nerve axons in the 
CNS [102]. Myelin is necessary for salutatory axonal conduction to occur. Therefore, 
demyelination destroys nerve conduction that results in a number of neurological signs 
and symptoms and neurophysiological findings that is often found in multiple sclerosis. 
Along with delays in conduction of evoked potentials, action potentials travel at much 
lower velocities in demyelinated axons [102]. Additionally, neural firing is a consequence 
of hyperexcitability of demyelinated axons and this may explain the flashes of light that 
occur with eye movement (phosphenes) and the electrical sensation that occurs running 
down the spine or limbs responsible for neck flexion (L'hermitte sign) [102]. Even though 
the frequency of firing increases, demyelinated neurons experience problems in 
sustaining an action potential along the axonal length. As a result, the nerve fatigues 
with repeated usage causing transient neurological deficits especially after exercise or a 
hot bath (Uhthoff phenomenon). MS patients thus grow tired upon engaging in physical 
activity or tasks requiring mental prowess and recover slowly [102]. Neighboring axons 
are isolated physically and electrically by myelin sheaths. Cross-talk between adjacent 
axons (ephaptic transmission), causing paroxysmal symptoms like trigeminal neuralgia, 
ataxia, dysarthria, or painful tetanic posturing of the limbs, which lasts for a few minutes 
and occurs after a touch or movement [102]. After reorganizing at the cellular and 
systems level of the surviving functional pathways that are affected by the early 
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demyelination and inflammation [102], we observe clinical remission.  
Toxicity due to the inflammatory process of active lesions causes more injury to the 
participating tissue. Nitric oxide that is released by macrophages results in irreversible 
damage to axons and glia which promote the disintegration of the blood-brain barrier [103]. 
Transected axons in acute inflammatory MS plaques may experience Wallerian 
degeneration during the later 18 months without extending the lesion size or clinical deficit 
[102]. This is shown by both histology and imaging. Reactive astrocytes and microglia 
produce cytokines and growth factors throughout the acute inflammatory phase. These 
growth factors promote remyelination by surviving oligodendrocytes. Astrocytic 
proliferation (gliosis), however, may shield the chronic lesion, producing a physical barrier 
to further remyelination [102].  
Axonal injury may be worsened by the loss of trophic support by myelin or glia with 
no further axonal degeneration and accumulating clinical deficits [102]. Along with the large 
oligodendrocyte loss, the degree of acute axonal injury which is measured by the 
expression of amyloid precursor protein (APP), along with the extent of chronic axonal 
loss relative to the PPWM, correlate with the degree of demyelination and nature of the 
inflammation [93, 104]. Acute axonal injury shows a positive correlation to the density of 
macrophages and CD8 cytotoxic T-lymphocytes within MS lesions, whether 
demyelinating, inactive, or remyelinating. No correlation exists with the expression of 
TNF-α or inducible nitric oxide synthetase (iNOS). Acute axonal injury is the worst in 
secondary progressive MS compared to those with primary and the most severe in 
secondary progressive MS compared to those with primary progressive (PPMS), or 
relapsing-remitting MS (RRMS) [104]. Acute axonal injury may occur without myelin 
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degradation, which suggests that an ischemic factor contributes to pathogenesis of the 
lesion [93, 104].  
  It is believed that disability occurs only after reaching a threshold of axonal loss 
after which compensatory CNS resources are used up [105-106]. Therefore, chronic 
progressive axonal loss may cause progressive neurological decline which is typical of 
primary progressive MS [93, 104]. Along with the variable patterns of demyelination and 
cellular composition, heterogeneity occurs amongst MS lesions with respect to degree 
of axonal damage.  
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1.3 Cellular Biology of Remyelination in MS 
Literature suggests that remyelination occurs in some demyelinated areas. 
Therefore, it should be possible to myelinate myelin-deficient areas by transplanting 
glial cells in experimental models of MS [107-110]. It is important to understand the 
background behind the success or failure of endogenous remyelination in MS because 
some areas may show remyelination while others may not. Understanding the 
molecular basis of remyelination is imperative to design possible remyelinating 
transplantation. For remyelinating transplantation, it is important to answer a few 
important questions such as i) which cell leads to the production of remyelinating 
oligodendrocytes, ii) over what distance can these cells be recruited into a demyelinated 
region, and iii) can the cells move freely within the adult CNS and within demyelinated 
areas.   
Two major differences exist in myelin sheaths in remyelinated areas: i) they are 
thinner than normal [111] and ii) internodal length is greatly reduced [112]. It has been 
insinuated that the large oligodendrocyte number is needed for remyelination since it is 
stated that oligodendrocytes are greater in remyelinated areas in EAE and MS lesions 
[113-114]. These extra cells may have emerged from a number of sources. It is being 
suggested that oligodendrocytes may survive myelin sheath loss in acute MS lesions 
[115-116] which means that it could directly remyelinate the demyelinating axons or 
proliferate itself with or without dedifferentiating quality to produce new oligodendrocytes 
[117-119]. Oligodendrocytes from the surrounding demyelinated areas may be induced to 
proliferate [120-121]. Another explanation is that the oligodendrocyte that has already 
generated myelin sheaths can not undergo further proliferation. Consequently, fresh 
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oligodendrocytes from progenitor cells are needed for remyelination to occur. Progenitor 
(neural stem) cells are present in the adult nervous system [122-123]. These cells arise 
from demyelinated areas where they may survive or migrate into the required region 
from the nearby normal tissue. However, studies have found that both precursors and 
differentiated oligodendrocytes act as potential cells for remyelination [124]. 
1.3.1 Mitosis and Remyelination 
Remyelinating demyelinated areas is produced by cells undergoing mitosis [124-
127]. Preventing mitosis via experiments involving irradiation has shown that mitosis is a 
prerequisite for any remyelination [107, 128].  
1.3.2 Proliferation of Oligodendrocytes 
 
No conclusive evidence of remyelination triggered by demyelinating axons 
presently exists [129]. Proliferation of oligodendrocytes can not begin by demyelinating 
axons. Therefore, there is no remyelinating potential.  
Contrasting with the above results, transplanting the embryonic human brain 
fragments into newborn mice causes myelin sheath formation [130-131] while the adult 
human brain does not cause myelin sheath formation even though the transplanted 
cells do survive [132]. 
In conclusion, mitosis is a requirement for remyelination [118, 124-127] and the 
majority of remyelinating oligodendrocytes are derived from progenitor cells [130-131].  
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1.4 Clinical Presentation  
9 Relapsing – 85-90% at onset 
9 Primary progressive – 10% and older age at onset 
9 Secondary progressive: 
¾ Develops in up to 80% of relapsing patients 
¾ 5-15 years after onset 
 
1.4.1 Initial Clinical Symptoms in Relapsing-Remitting MS 
Symptoms are categorized in neurologic terms (numbness, weakness, and 
tremors) and functional changes like increased difficulty with handwriting or 
buttoning clothes, increased difficulty with walking, running, or leg coordination, or 
difficulty tracking with reading. Some of the most common symptoms are changes 
in visual function which can take the form of monocular (rarely binocular) 
decreased visual acuity or blurred vision, which is described as “looking through a 
fogged window or smudged eyeglasses,” often involving central vision more than 
peripheral vision. Loss of color intensity where everything appears “bleached” or 
lighter is less common. In some cases, loss of vision occurs due to inflammation 
of the optic nerve as opposed to optic chiasmal lesion. There may be a sharp or 
dull pain behind and over the eye which is worse with eye movement, and at 
times, preceding the onset of visual difficulty by days to weeks. In MS, these 
visual difficulties are most likely due to optic nerve inflammation (optic neuritis) 
and can occur over a few hours or days. It may subside without treatment over 
weeks to months.  
Sensory symptoms in MS also occur commonly. Their onset, in contrast to 
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sensory changes of compressive neuropathies or radiculopathies, is usually painless, 
with a few exceptions [133]. Patterns of sensory change differ widely. In some cases, 
they involve particular dermatomes, such as the C7-T2 dermatomes, hands, feet, and 
legs. Gradually, ascending sensory symptoms are common and which involve tightness 
in the abdomen or thorax (“like a girdle or rope”). Facial and tongue numbness and 
tingling are less frequently noted. Symptoms may be unilateral or bilateral and can be 
made worse with fatigue or increased body temperature. The nature of the sensory 
changes vary and can range from numbness, to numbness and tingling, to a 
dysesthetic, uncomfortable, prickling, and often burning sensation (causalgia). These 
sensory changes are not MS-specific and if present bilaterally and associated with a 
buzzing, electric, shock-like sensation into the back and/or limbs upon neck flexion 
(L’hermitte sign), indicate the presence of spinal cord dysfunction. Along with problems 
with vision, symptoms may spontaneously resolve partially or completely over a period 
of days to weeks. Vertigo or feelings of imbalance or dizziness are among the most 
common symptoms in any clinical practice of neurology and can be related to 
medication, blood pressure changes, inner ear (vestibular) dysfunction, musculo-
skeletal abnormalities of the neck (cervical vertigo) and, of course, brainstem 
dysfunction in MS. The dizziness and vertigo of CNS origin can be positioned and made 
worse with rapid eye movements but it is unusual for tinnitus and decreased hearing to 
be present. Since inflammation of the brain stem in MS often involves other nuclei, the 
vertigo associated with MS is often associated with other symptoms such as diplopia, 
oscillopsia, dysarthria, and/or numbness. Vertigo occurs in some people with MS and is 
most often due to inner ear dysfunction instead of central nervous system inflammation 
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[134], and deciding whether a previous episode of vertigo was of central or peripheral 
origin can be difficult.  
Double vision with or without oscillopsia (the symptom of nystagmus, with 
bouncing or jumping vision) can be a symptom of MS. Pupillary or eyelid changes are 
not usually associated with diplopia but is often present on gaze to either side and 
vertically.  
MS patients also often exhibit weakness which is seen after extended exertion 
(“My right leg begins to drag only after I’ve walked five miles”), or with elevations of core 
body temperature like with infections or hot weather. Weakness may involve any body 
part but most commonly affects the lower extremities, either proximally or distally. 
Muscle cramping or myoclonic jerks are the muscular symptoms that occur, especially 
when lying down at night.  
Fatigue occurs most commonly with MS. This type of fatigue is the kind one feels 
after a period of flu or other viral infection, namely, a type of fatigue that rest alone does 
not undo and which is best described as a generalized feeling of weakness. It can be 
mild or severe and can be a major symptom during MS.   
1.4.2 Symptoms of Primary Progressive MS 
The symptoms in people with primary progressive MS may appear in such a way 
that determining the time at which the disease occurred becomes difficult and can only 
be narrowed to months or years. Additionally, visual or cranial nerve symptoms occur at 
the beginning of primary progressive MS and are most unusual in keeping with the 
pathophysiology of the disease, which mainly involves the spinal cord. Most common 
symptoms include increasing imbalance, extremity weakness, limb tightness, numbness 
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and tingling of either a limb or limbs (primarily the legs), and often the lower trunk, with 
changes in bowel, bladder and sexual function, similar to those noted with relapsing-
remitting MS. This pattern of neurologic change is not unique to people with primary 
progressive MS.  
1.4.3 Signs in Multiple Sclerosis 
In general, neurologic exam results are appropriate for the symptoms of an 
individual.  
Visual difficulties of an optic neuritis – Visual acuity declines and not 
corrected with glasses, defects in the visual field, loss or decrease in 
color intensity, edema of the optic nerve (less common).  
 
Sensory changes in MS often will not be sharply defined: Diplopia – 
internuclear ophthalmoplegia (INO), or an abducens weakness. 
 
Limb weakness – muscle weakness, with or without changes in tone may 
be with spasticity, increased reflexes, and Babinksi responses. 
  
 The biologic onset of MS occurs before the initial clinical presentation of 
symptoms. The MRI shows a much more silent disease than is associated with clear 
clinical symptoms and signs. 1 in 10 new T2 or contrast-enhancing lesion is associated 
with the appearance or worsening of a symptom. As a result, there may be findings on a 
neurologic exam that were observed by the individual and were not linked to any 
symptom.  
The presence of certain symptoms and signs may suggest a diagnosis of MS, 
however their absence can make the diagnosis doubtful. It has been suggested that a 
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set of so-called red flag negatives that should cause a diagnostician pause [136]. These 
include the absence of objective optic nerve or oculomotor findings, the absence of 
clinical remissions, the absence of sensory findings, the absence of bowel or bladder 
difficulties, and normal or atypical MRI and CSF findings. None of these completely 
excludes MS, especially early on during the MS disease or in persons with variants of 
MS, such as those with primary progressive MS. A patient’s disease history, apart of 
MS, should be considered if the patient has had a long neurologic history and several of 
the above negatives [135].  
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1.5 Diagnosis and Management 
1.5.1 Magnetic Resonance Imaging (MRI) 
Using MRIs have made diagnosing MS both simpler and more complex. Since 
MS is an inflammatory disease of the CNS, MRIs are able to visualize changes in a 
patient. However, the changes seen in MRIs are changes in proton density (water 
content) and therefore are nonspecific.  
MRI changes should therefore never be solely used to diagnose MS, irrespective 
of the claims of the radiology report. However, certain changes in MRI are very 
indicative of MS. MRI changes seen associated with the disease correlate with the 
gross and histologic pathology of the disease [136-137].  
1.5.2 CSF Analysis 
Up to 90% of people with clinically definite MS have spinal fluid that exhibits 
changes of low-grade inflammation. These changes are both measured directly in CSF, 
such as the immunoglobulin G (IgG) concentration and oligoclonal bandings, are 
calculated from measuring CSF and serum IgG, and albumin. Using certain formulae, 
calculated values include the IgG index and IgG synthesis rate. The presence of these 
changes is influenced by both the progression of the disease and the anatomic location 
of the inflammatory lesions. Those near ventricular surfaces will result in spinal fluid 
problems. However, with greater involvement of the blood-brain barrier, the specificity of 
the calculated changes seen in MS CSF (like IgG synthesis rate) decreases [138]. Early 
during the progression of the disease, the spinal fluid is often normal [139] but can 
deteriorate over time [140]. Spinal fluid changes at this stage are imperative in diagnosing 
MS. In up to 20% of patients with clinically definite MS, the spinal fluid is normal [141], 
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probably due to differences in the disease pathogenesis in these individuals [142]. 
However, the presence of a low-grade inflammation in CSF without the occurrence of 
other diseases could cause similar changes which would support an MS diagnosis.  
1.5.3 Management 
The following is the treatment modality employed by the Mayo Clinic and other 
centers in USA.  
1. Symptomatic treatment 
i. Corticosteroids 
ii. Spasticity: Mild spasticity can be managed by stretching and exercise 
like water therapy, yoga and physical therapy. Medication like baclofen 
(lioresal), tizanidine (zanaflex), gabapentin (neurontin), and 
benzodiazepines are effective antispastic agents for stiffness that 
interferes function or sleep  [143] 
iii. Paroxysmal Disorders: Carbamazepine (Tegretol) [144], and for 
paroxysmal pain anticonvulsants or amitriptyline (elavil) are effective [145] 
iv. Bladder urgency: Oxybutynin (Ditropan) and Tolterodine (Detrol) [146] 
v. Fatigue-reducing medications: Amantadine (Symmetrel) [147] and for 
narcolepsy – Modafinil (Provigil) [148] 
vi. Depression: Selective Serotonin Reuptake Inhibitors (SSRIs) like 
Amitriptyline [149] 
vii. Sexual Inadequacy: Sildenafil (Viagra) [150] 
2. Disease-Modifying Therapies: 
a. Interferon β-1a (Avonex), Interferon β-1a (Rebif), and Interferon β-
1b (Betaseron) [151] 
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b. Glatiramer (Copaxone) for β interferon intolerant patients [152] 
c. Mitoxantrone [153] 
3. New and Other Drugs: 
i. Natalizumab (Antegren), a monoclonal antibody against VLA4 [154] 
ii. Other drugs: IV IgG, azathioprine, methotrexate, and 
cyclophosphamide [155-159] 
4. BMT: Autologous Bone Marrow Transplantation has been tried by Dr. 
George Kraft’s group [160] from Seattle, USA and by the cohort study of 
Canadian MS BMT Study Group [161]. The interim results have been 
encouraging 
5. Statins: Atorvastatin has been found promising in their animal (EAE) 
study by Scott Zamvil and his colleagues [162] from University of California, 
USA and in-vitro human study from the German and Austrian group [163] 
6. Experimental: Plasma exchange therapy for sudden and severe attacks 
of MS that are not responding to high doses of corticosteroid. 
 
 
 
 
 
33 
 
1.6 Animal Model of MS 
1.6.1 Experimental Allergic (Autoimmune) Encephalomyelitis (EAE) 
 Animal models for the disease are necessary to understand the 
complexity of the human disease. Since we are unable to go inside the 
human disease process, the animal models enable us to study the disease 
progression. Animal models to study disease have been used since ancient 
times. Sacrificial animals were first used to observe the internal organ 
pathology. Autoimmune diseases were best characterized in animal models.  
Multiple sclerosis (MS) is a difficult organ-specific autoimmune disease 
to model. Autopsies are usually limited and confirm the existence of a long-
established disease. Biopsy and autopsy examinations show that an 
autoimmune process had occurred but since the disease process is found in 
the central nervous system (CNS), it is difficult to obtain or analyze biopsies 
or draining fluids that allow detailed monitoring of the disease progression. 
Only recently did imaging of live patients become possible, which allowed us 
to learn about previously inaccessible stages of the disease. 
Experimental Autoimmune Encephalomyelitis (EAE), also known as Experimental 
Allergic Encephalomyelitis, is an animal model of Multiple Sclerosis. Animal models of 
human diseases are diseases that occur in non-human species (especially rodents) 
which are similar to the human form of the disease. This allows us to study and gain a 
better understanding in treating the human form. EAE is not multiple sclerosis. It is also 
not a single disease specific to only one species, but its different forms are very similar 
to the stages of MS. 
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EAE is an acute or chronic-relapsing, acquired, inflammatory autoimmune 
disease which is also characterized by demyelination. Animals are injected with whole 
or parts of different proteins that make up myelin, the insulating sheath which surrounds 
nerve cells (neurons). An autoimmune response results from the proteins in these 
animals. In other words, the animal’s immune system attacks its own myelin due to 
exposure of the injection. The animals develop a disease process that is very similar to 
MS in humans. This process is expressed in fig. 1.6. 
 
 
  
  
Fig. 1.6: EAE pathogenesis causing myelin damage. The inoculated myelin antigen is processed in 
peripheral lymph nodes and presented to lymphocytes resulting in their clonal expansion of B-cells and T-
cells. These cells migrate into the CNS where they are reactivated upon recognition of the myelin antigen. 
B-cells secrete antibodies directed against myelin antigen. The autoreactive T-cells recognize antigen 
presented by CNS resident microglia and secrete cytokines that. These cytokines induce MHC expression 
on CNS resident cells, disrupt the blood brain barrier to allow further cellular infiltration, and attract 
peripheral macrophages, further enhancing the immune response. 
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1.6.2 Historical Perspective 
EAE was initially discovered as a side-effect of the rabies vaccination in the 
beginning of the 20th century [164]. EAE was induced in mice by Olitsky in 1949 [165]. In 
1947, Kabat stated that self antigens found in CNS white matter were the cause of EAE 
[166]. In 1962, Einstein discovered myelin basic protein (MBP), which makes up 30% of 
CNS myelin, as an encephalotogenic antigen in CNS tissue [167]. 
In 1933, Thomas Rivers identified experimental autoimmune encephalomyelitis 
(EAE), an autoimmune inflammatory demyelinating disease, as a model for ADEM [168-
169].  
EAE has been found in several animal species such as mice, rats, guinea pigs, 
rabbits, macaques, rhesus monkeys and marmosets. For several reasons including the 
number of immunological tools, the availability, lifespan and animal fecundity and the 
similarity of the induced disease to MS, mice and rats are the most commonly used 
species.  
The animals are in-bred to induce susceptibility to EAE. Such as with humans 
and MS, not all mice or rats will have a natural tendency to acquire EAE. However, 
different breeds will develop different forms of EAE, some of which act as good models 
for the different human forms of MS. Different EAE forms are also used as models for 
the different stages in MS.  
Many proteins or protein parts (antigens) are used to induce EAE such as: myelin 
basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein 
(MOG).  
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1.6.3 EAE Pathogenesis  
 To produce EAE, four integrins must be expressed on activated T-lymphocytes 
[170]: MBP-specific T-lymphocytes produce a tumor necrosis factor (TNF) and interferon-γ 
(IFN-γ) - cytokines of the helper T-cell subset 1 (TH1) type [171]. These cytokines are 
responsible for the upregulation of VCAM expression on CNS endothelial cells which 
promotes the binding of four integrins expressing T-lymphocytes to endothelium and 
upregulation of expression of MHC class II molecules on APCs within CNS [172-173]. T-
lymphocytes interact with ICAM-1 and VCAM-1 and become attached to the ECs, then 
migrate in [170]. 
Interferon-α (IFN-α) induces interleukin-12 (IL12) [174-175]. IL12 treatment makes 
EAE worse and antibody to IL12 improves the disease [174-176]. IL4 and IL10 (TH2) improve 
MBP-induced EAE, where TH2 downregulates TH1 [177-179].  
1.6.3.1 T-lymphocytes Require Two Signals 
9 TCR recognize antigenic peptides within MHC complexes on APCs. 
9 Other receptors (costimulatory) on T-cells that bind to their respective ligands on 
APCs. 
As a result, B7-1 and B7-2 ligands on APCs with CD28 and CTLA-4 receptors on 
T-lymphocytes play a role in EAE [180-182].  
Upregulated Chemokines at the EAE lesions are the following [183-186]: 
¾ macrophage inflammatory protein-1 
¾ monocyte chemotactic protein-1 
¾ neurotactin 
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Peripheral tolerance of myelin-specific T-lymphocytes experiences a break during 
relapsing EAE [183]. In lymphoid tissues, myelin-specific T-lymphocytes are activated in 
vivo. Therefore, different interactions in the pathogenesis are potential sites of 
therapeutic interventions. 
1.6.3.2 Nuclear Factor kappa B (NFκB) and Oxidative Stress  
NFκB is a DNA binding transcriptional factor complex that interacts with promoter 
areas in pro-inflammatory genes [184]. Oxidative stress causes an activation of the 
transcriptional factor NFκB, that in turn upregulates pro-inflammatory gene expression 
[185]. Strong inducers of NFκB activation are the gram-negative bacterial endotoxin 
lipopolysaccharide (LPS), and the cytokines tumour necrosis factor – α (TNF-α) and 
interleukin-1β (IL-1 β) . Most of the identified stimuli for NFκB activation, including LPS, 
TNF-α, and IL-1β, manufacture oxidative stress in cells [186,187]. The over expression of 
glutathione peroxidase [188] inhibits the cytokine-induced activation of NFκB. The TNFα-
induced NFκB activation is attenuated by over expression of γ-glutamylcysteine 
synthase, which is the rate-limiting enzyme for GSH synthesis [189]. 
1.6.3.3 NFκB and Pro-Inflammatory Gene Expression 
Activation of NFκB promotes transcription of pro-inflammatory genes that include 
cell adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and 
VCAM-1, enzymes such as inducible nitric oxide synthase (iNOS) and cycloxygenase-2 
(COX-2), cytokines such as IL-1β, interleukin-6 (IL-6) and TNFα, and chemokines such 
as regulated upon normal T-cell expressed and secreted protein (RANTES), monocyte 
chemoattractant protein-1(MCP-1), interleukin-8 [190-195]. 
One should be able to inhibit inflammatory changes by decreasing the activation 
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of NFκB. Lessening the chances of the activation of NFκB should be achievable by 
promoting the scavenging of strong oxidants formed by normal and abnormal cellular 
metabolism. To do this rationally requires an understanding of the significant 
components of the cellular anti-oxidant defense systems. 
1.6.3.4 EAE and Oxidative Stress 
The inflammatory infiltrate in the lesions of EAE that comprises mononuclear 
infiltrate in the parenchyma of brain and spinal cord and also around blood vessels as 
perivascular cuffing plays an important role in causing the damage to myelin and 
oligodendrocyte. The mononuclear infiltrate is attributed with enzymes that produce 
reactive oxygen species (ROS) [196-198]. Thereby it is being said that oxidative stress 
contributes significantly in the pathogenesis of MS [199, 200]. The activated microglia 
and/or macrophages generate ROS through actions of NADPH oxidase enzyme. [201]. 
Damaging effects of superoxide most likely contributes to the injury of oligodendrocytes 
in vitro [202]. The cyclo-oxygenase 2 (COX-2) enzyme also produces ROS [203]. The nitric 
oxide (NO) is generated by inducible nitric oxide synthetase (iNOS) enzyme using 
arginine, oxygen and NADPH [204]. Nitric oxide acts by various means. It can induce 
COX-2 enzyme [205, 206].  It reacts with superoxide to form the highly toxic species 
peroxynitrite that can damage proteins, cell membrane and nucleic acids [207, 208]. The 
peroxynitrite can react with tyrosine to produce nitrotyrosine. The nitrotyrosine is found 
in the demyelinating lesions of EAE. This attributes the damaging effects of peroxynitrite 
[209]. 
 The white matter is rich in iron and it can convert hydrogen peroxide to hydroxyl 
radicals that may contribute to demyelination [198]. The reduced form of iron (ferrous ion 
39 
 
[Fe2+]) is used for this reaction, which is called the Fenton reaction [210]. The oxidised 
ferric ion (Fe3+) formed in this reaction can be reduced back to form ferrous ion (Fe2+) 
by vitamin C, thereby a continuous reaction with hydrogen peroxide to generate 
hydroxyl radical [210]. Therefore, the large doses of vitamin C may be harmful in MS [211]. 
Vitamin C does not give protection against EAE, and it may increase lipid peroxidation 
in the presence of Fe3+ [212]. Lipids make nearly 70% of myelin. This contributes in lipid 
peroxidation leading to damage to myelin [213-215].   
The oxidative stress in different demyelinating diseases is expressed below in fig. 
1.7 [216]. 
 
Fig. 1.7: Oxidative stress in a demyelinating disease. The interaction between NO and ROS to form peroxynitrite 
catalysed by iNOS. In Fenton reaction, the iron contributes to produce hydroxyl radical, and vitamin C in reducing 
ferric ions to ferrous ions required in the Fenton reaction. Arg = arginine; COX-2 = cyclo-oxygenase 2; H2O2 = 
hydrogen peroxide; iNOS = inducible nitric oxide synthase; NADP = nicotinamide adenine dinucleotide phosphate; 
NADPH = reduced NADP; NO = nitric oxide; NOS = nitric oxide synthase; O2– = superoxide; OH– = hydroxyl radical; 
ONOO– = peroxynitrite; ROS = reactive oxygen species.  
 
 As literature on EAE suggests, there have been various attempts to use chemical 
antioxidant for therapeutic intervention in animal experimentation with generally 
encouraging and successful results of various grades. The following table 1.1 presents 
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the various antioxidant used by different research groups. 
Table 1.1: Effects of different antioxidants in EAE 
 
 The modes of damage to myelin and axons are thought to be an autoimmune 
injury followed by apoptotic damage. This injury is possibly caused by reactive oxidative 
Antioxidant Effects in EAE 
Caffeic acid phenethyl ester (CAPE) [217] Decreased severity of disease and decreased levels of reactive oxygen species 
Lipoic acid [218-219] Decreased inflammation, demyelination, and axonal loss 
Phenidone (cyclo-oxygenase/lipoxygenase 
inhibitor) [220] Decreased incidence and severity of disease 
N-acetylcysteine amide (AD4) [221] Decreased inflammation, demyelination, axonal loss and clinical symptoms 
Trichostatin A (TSA) [increases levels of  
antioxidant enzymes] [222] 
Decreased inflammation, demyelination, axonal 
loss and clinical symptoms 
Bilirubin [223] Prevented acute and chronic EAE (protected permeability of blood-brain barrier) 
Thymoquinone [224] Decreased incidence and severity of disease 
t-Butylhydroxyanisole (BHA) [225-226] Decreased incidence and severity of disease 
Uric acid [227-228] Prevented disease symptoms 
Hemin (inducer of haeme oxygenase-1) [229] Inhibited EAE 
Epigallocatechin-3-gallate (EGCG) [green 
tea constituent] [230]  Inhibited EAE 
Metallothionein [231] Prevented demyelination and axonal damage, promoted tissue repair 
Flavonoids [232] Delayed recovery of clinical symptoms 
41 
 
species (ROS)-induced apoptosis in CNS and peripheral nervous system in addition to 
the injury caused by autoimmunity. This mode of damage is illustrated in fig. 1.8 [233] 
 
Fig. 1.8: Pathways and mechanisms of Ras-mediated protection from reactive oxidative species (ROS)-induced 
apoptosis. Transformation of human ovarian epithelial cells by oncogene Ras leads to the enhanced expression of 
several antioxidant proteins involved in major cellular pathways for ROS metabolism. Protein targets up-regulated in 
transformed HOSE are highlighted with an arrow. These proteins include thioredoxin peroxidase, peroxiredoxin 3 (a 
mitochondrial member of thioredoxin peroxidases), NADH dehydrogenase ubiquinone Fe/S protein, selenophosphate 
synthetase, and mitochondrial superoxide dismutase. In conjunction, these proteins significantly increase the overall 
antioxidant capacity and protect cells from apoptosis under high level of ROS. 
 
1.6.3.5 Phase 1 and Phase 2 Enzymes 
Phase 1 and phase 2 enzymes are involved in xenobiotic metabolism. 
Xenobiotics are chemicals that are alien to the body or to live organisms. These 
xenobiotics are metabolized by enzymes placed into phase 1 (mono-oxygenases such 
as cytochrome P450s) and phase 2 categories of enzymes [234]. The phase 1 enzymes 
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are electrophiles (electron receiver/lover). These phase 1 enzymes generally oxidize or 
reduce xenobiotics, though they usually give rise to potentially harmful secondary 
products [235]. The products of phase 1 enzymes are acted upon by phase 2 enzymes 
that cause a conjugation reaction. These phase 2 enzyme conjugates are comparatively 
easy for excretion. The enzymes like γ-glutamyl-cysteine synthase, quinone reductase, 
glutathione transferase, epoxide hydrolase, UDP-glucoronosyltransferase are very 
important phase 2 enzymes [235], including the selenoprotein family of thioredoxin 
reductases [236]. Directly or indirectly, the phase 2 enzymes have an essential role in 
inactivating xenobiotics, often by forming conjugates, as glutathiyl-xenobiotic 
conjugates. In contrast, there has been broad research on phase 2 enzymes and their 
induction (particularly quinone reductase and glutathione S-transferases) in cancer 
prevention [235,237,238]. 
1.6.3.6 BHA and BHT 
Two commonly used food additives are butylated hydroxyanisole (BHA) and 
butylated hydroxytoluene (BHT). The dietary intake of BHA [239-241] and BHT increases 
tissue phase 2 enzyme activities [242]. BHA is apparently mediating its phase 2 enzyme 
induction by its metabolite BHT [243]. The glutathione peroxidase is one of the phase 2 
enzyme can be induced by tetra-butylhydroxyanisole (BHA). BHA is a food preservative, 
which also increases the glutathione (GSH) [225-226]. This reiterates again that EAE can 
be improved by antioxidants [217-232], thereby having a useful potentials in the 
management of MS. 
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1.6.3.7 Phase 2 Enzyme Inducers, GST, and Peroxide Scavenging 
The green tea (polyphenolics) has been shown to induce glutathione S-
transferase and quinone reductase in a variety of tissues in mice [244]. The soy ingestion 
also increases quinone reductase and glutathione S-transferase in various tissues [245]. 
It is apparent that there must be efficient mechanisms that scavenge hydrogen peroxide 
and organic peroxides. Two defined enzymatic mechanisms, whereby the cell can 
scavenge hydrogen peroxide, are known as the catalase and the glutathione peroxidase 
(GPx) systems. Of the two, the GPx system appears to be the most important [246, 247]. 
The GPx family of proteins is selenoproteins that can scavenge hydrogen 
peroxide and organic peroxides, as well as lipid peroxides. Contrasting with catalase, 
these enzymes have a high affinity for their substrate [248-250]. GPx uses the tripeptide 
GSH (glutathione) as the electron donor in the scavenging of peroxides [250, 251]. The 
GSH is made up of three amino acids: glutamic acid, cysteine, and glycine.  With the 
GSH-dependent GPx’s, because of the sequential reactions of two GSH molecules with 
glutathione peroxidase in the scavenging of peroxide, increasing GSH concentrations 
clearly increases the peroxide scavenging efficiency [252]. Many lipid peroxides as well 
as peroxide breakdown products, such as 4-hydroxyalkenals, are scavenged by 
glutathione S-transferase which causes the creation of inactive glutathiyl adducts [253-
255]. 
Thus, the GSH plays several critical roles in minimizing oxidative stress; it is 
essential for: i) peroxide scavenging by GPx, ii) scavenging of 4-hydroxyalkenals and 
other oxidants by glutathione S-transferase, and iii) for the ultimate regeneration of 
vitamin E. 
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The advanced glycation end products (AGEs) seen in diabetes mellitus affect 
cellular metabolism by the inactivation of affected proteins; for example, glycation of 
glutathione reductase inactivates this enzyme [256] which plays a significant role in 
decreasing oxidized-glutathione. Undeniably, a negative relationship exists between the 
extent of diabetic complications and erythrocyte GSH level [257], which is perhaps due, in 
part, to glutathione reductase inactivation. GSH plays a chief role in preventing the 
formation of AGE. The decreasing red blood cells GSH increases hemoglobin glycation 
[258]. Therefore, GSH inhibits the formation of AGEs most likely through the glyoxalase 
pathway [259]. This is just another example of the many important roles that GSH plays in 
reducing and minimizing oxidative stress. 
In combination with the increased inefficiencies of mitochondrial respiration are 
reduced abilities by ageing cells to synthesize GSH, to reduce GSSG to GSH [260], as 
well as decreased activities of GPx [261-263], superoxide dismutase and catalase [262, 263]. 
1.6.3.8 Anti-Oxidant Defense System 
The important components of the anti-oxidant defense system are the following:  
a) Scavenging of peroxides, as peroxides can give rise to strong oxidants such as 
hydroxyl/peroxyl radicals, 4-hydroxyalkenals and pro-inflammatory isoprostanoids 
b) Regeneration of vitamin E, since vitamin E plays a necessary role in preventing lipid 
peroxidation chain reactions  
c) Scavenging α-oxo-aldehydes, as these strong oxidants can form AGEs 
d) Scavenging 4-hydroxyalkenals, because these strong oxidants can also form AGEs 
and inactivate protein function via the formation of protein carbonyls;  
e) Scavenging of quinone radicals  
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Thioredoxin-dependent peroxidases, which utilize thioredoxin as the electron 
donor, may also play an imperative role in scavenging peroxides [264]. Glutathione S-
transferases eliminate many electrophiles by catalyzing the development of the 
glutathiyl adducts [253]. Additionally, quinone reductase plays an important role in 
reducing quinones, such aminochrome [265]. GSH plays vital roles in numerous 
scavenging activities, either as being the electron donor in the reduction of oxidants or 
by forming glutathiyl adducts with the oxidants [266].  
How do cells manage oxidative stress? There are anti-oxidant defense enzymes 
that play major roles. Superoxide anions are converted into H2O2 by superoxide 
dismutases (SOD). H2O2 is turned into water (H2O) and oxygen using catalases or 
glutathione peroxidases (GPX). GPX activity requires the presence of glutathione 
(GSH). The biochemical reactions that lead to the detoxifying role of antioxidant are 
expressed below in fig. 1.9 [216]. 
Fig. 1.9: Antioxidant activity 
 
Oxidation states of oxygen. Oxygen can be reduced to form water by the addition of four electrons. The intermediates 
(reactive oxygen species) are free radicals and are highly reactive with other molecules. H2O2 = hydrogen peroxide; 
O2– = superoxide; OH– = hydroxyl radical. 
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1.6.3.9 Inflammatory Demyelination 
 MS is not a monolithic disease. One aspect that is recurring with most MS 
variants is immune inflammation with demyelination and almost all animal models 
involve inflammatory demyelination as a prerequisite. The three most common 
inflammatory diseases of the CNS which exhibit differing levels of demyelination and 
axonal damage are MS, viral infection, and acute disseminated encephalomyelitis 
(ADEM). Etiological links between these diseases are hypothesized. A great deal of 
anecdotal and pathological evidence exist which uses viral infection to act as a trigger 
for MS, and ADEM often uses a postviral or postvaccination encephalomyelitis [267]. It is 
not surprising, therefore that the two most commonly studied genres of animal models 
for MS are infection with a neurotropic virus and a broad range of autoimmune diseases  
that are grouped together as experimental autoimmune encephalomyelitis (EAE). 
Thomas Rivers established this autoimmune inflammatory demyelinating disease as 
EAE in 1933 as a model for ADEM [41].  
Generically, though varying by strain and protocol, EAE and neurotropic viral 
models show inflammation, demyelination, and axonal damage. Using such models has 
improved our understanding of MS but may have also biased it. 
The reactions catalysed by the antioxidant enzymes: 
(a) superoxide dismutase (SOD), (b) catalase (Cat); 
and (c) glutathione peroxidase (GPx). GSH = 
glutathione; GSSG = oxidized form of GSH; H2O2 = 
hydrogen peroxide; O2– = superoxide. 
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1.6.4  Molecular Immunopathology of EAE 
 
1.6.4.1 Innate Immunity 
Immune stimulation is needed to model an inflammatory disease. Innate immunity 
is important to initiating immune responses. The term “innate immunity” refers to a wide 
spectrum of preprogrammed responses to infection or ligands specific to infectious agents. 
An evolutionarily ancient recognition and signaling system forms the foundation of 
pathogen recognition by innate components. The Toll-like receptors (TLRs), eleven of 
which have been described thus far, are called this because of their homology to Toll 
receptors, which were first described as being important in the development of the nervous 
system in Drosophila. TLRs bind ligands that are uniquely expressed by microbes, fungi, 
and viruses. Pathogen-derived epitopes are called pathogen-associated molecular 
patterns (PAMPs). Production of cytokines is induced by TLR signaling, especially the type 
I interferons, which are responsible for early cellular responses to viral infection and 
chemokines which leads to leukocyte entry to the CNS. TLR-induced cytokines are 
responsible for an adaptive or antigen-specific lymphocyte response and direct the quality 
of these responses. Therefore, TLR-expressing cells in mucosae, epithelia, and endothelia 
are both found and appropriately equipped to serve as a frontline defense against 
pathogens. TLR-expressing cells are also found in the CNS and have been shown to 
exhibit early responses to PAMPs 
1.6.4.2 Adjuvant and Its Effects 
Initiating T-cell immune responses and thus of adaptive immune 
responses generally is dependent on adequate provision of co-stimulatory 
signals. These are provided through ligating signaling receptors on T-cells by 
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co-stimulator ligands expressed on antigen-presenting cells (APCs). Expressing 
adequate levels of co-stimulator ligands by APC is induced through TLR signals 
along with other signals including cytokines, several of which are TLR-inducible.   
Using adjuvants is grounded in this immunological basis. Administering a 
potential antigen along with an adjuvant aids in its recognition in a co-stimulator 
adequate milieu, thereby promoting an immune response. It is important to 
recognize that adjuvants are needed for experimental initiation of immune 
responses, unless the immunogen is itself a TLR ligand (e.g. bacteria, viruses). 
The quality of the immune response induced is impacted by the nature of the 
TLR ligand. Therefore, the choice of adjuvants directs the nature of the immune 
response. Moreover, it is essential to recognize that choices are limited based 
on what works. This allows the discussion to address the issue of what facet of 
MS one wishes to model. Rodent models have been used to complete Freund’s 
adjuvant (CFA) with an approach that focuses on inflammatory pathology along 
with the need for aggressive immunization to overcome self-tolerance. This oil-
based emulsion utilizes heat-killed M. tuberculosis as its active ingredient. The 
issue of the appropriateness of using the delayed-type hypersensitivity (DTH) 
reaction in furthering our understanding of MS remains unresolved.  
Pertussis toxin (PT), or heat-killed Bordetella pertussis¸ is often used as a co-
adjuvant, especially because the move toward gene-deficient “knockout” mice in EAE 
studies. A large majority of ESC lines used for the in vitro first step of homologous 
recombination in generating a gene knockout are from mice of the 129/J background. 
Most knocks are 129/J initially, and are most frequently back-crossed to C57B1/6. Mice 
49 
 
on the C57B1/6 genetic background are resistant to EAE induction. Inducing EAE in 
C57B1/6 mice always requires the use of PT along with CFA. This is now a popular 
model since the emergence of gene-deficient mice.  
Adjuvants are important for generating a sufficiently potent T-cell response to 
produce CNS inflammation. Neurotropic viruses act as their own adjuvants. Similarities 
shared between the inflammatory response to virus and that in EAE are used to support 
physiological relevance of the adjuvant-induced EAE model. The relevance of virus 
infection to MS might be questioned initially. This should always be kept in mind even 
though commentators would agree that this is not unreasonable.  
1.6.4.3 Immune Responses 
The CD4+ T-cell response can be divided based on cytokine production. The Th1 
versus Th2 division is one of the most long-lasting paradigms of modern immunology. 
Inflammatory CD4+ T-cells secrete Th1 cytokines, which is defined by interferon gamma 
(IFNγ) and tumor necrosis factor alpha (TNF-α). More importantly, Th1 T-cells express 
profiles of adhesion ligands and chemokine receptors that direct movement to tissues, 
and together with their cytokine profile, this is likely why Th1 T-cells were originally 
defined as cells that induced DTH responses. Both CFA and neurotropic viruses such 
as Theiler’s murine encephalitis virus (TMEV) steer the immune response towards a Th1 
profile. Excluding experimentally immunosuppressed or immunomodulated animals, Th2 
responses (which lack IFNγ and TNF-α, are dominated primarily by interleukins 4, 5, 
and 10, and are linked to antibody responses) fail to induce a MS-like disease in mice. It 
would not be wise to use this information to suggest that MS is a Th1 disease. MS may 
have some grounding in immunoregulation deficiency [268] and this can be seen from the 
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fact that myelin-specific Th2 cells can induce CNS inflammation in mice which are 
deficient in appropriate immunoregulatory systems [268]. Antibodies play a major role in 
MS, whether or not a Th2 response would be necessary for them to be produced [3, 269]. 
Recent reports suggest that antibodies may influence the quality of disease in MS, 
rather than play an initiating role; this is broadly consistent with experimental 
demonstrations of synergy between antibodies against myelin oligodendrocyte 
glycoprotein (MOG) and myelin basic protein (MBP) specific T-cells for inducing 
demyelinating EAE in rats [270-272]. The fact that CFA-based immunizations that are used 
to induce EAE can themselves induce antibody responses is often neglected. Whether 
such anti-myelin antibodies play an important role in EAE has been an important issue; 
most recent studies suggest that the nature of the myelin protein (peptide versus 
polypeptide, autologous versus xenogeneic) may influence their requirement [273-274]. 
1.6.4.4 CD4 & CD8 T- Cells 
In EAE models, the main infiltrating T-cell is the CD4 T-cell. The evidence from 
MS shows that CD8 T-cells may be more important in human disease [275] and are 
therefore implicated as cytotoxic effectors. Earlier studies showed that CD8 T-cells were 
either unnecessary for or played an immunoregulatory role in EAE [276-277]. Three recent 
papers showed the ability of CD8 T-cells to induce EAE [278-280]. However, only a minority 
of the views are represented in these papers. Therefore, the CD4 versus CD8 division is 
maintained as being an additional difference between MS and EAE. Therefore, viral 
models such as TMEV encephalomyelitis may be more reliable models for MS 
inflammation. 
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1.6.4.5 Selecting a Species 
The previous analysis has furthered the theme that one must choose which facet to 
model when designing animal models for a disease with a heterogeneous pathology. 
Experimental variables such as adjuvants may limit immunological models in ways that 
need careful consideration. A third consideration is whether the choice of animal species 
influences the behavior of the model. Rodents, especially mice and rats, are the most 
commonly studied experimental animals. These two species have replaced guinea pigs, 
hamsters, rabbits, and other species which were once routinely studied. Primate usage 
has gone up which is a reflection of earlier times when monkeys served as ADEM models 
[281]. Primates have several advantages as MS models. Like humans, their colonies are 
out-bred and there exists a high degree of homology between TCR and MHC which allows 
prediction of peptide specificities. The pathway to clinical application is therefore shorter 
than from rodents. The primate model of MOGp14-36 induced EAE in the common 
marmoset (Callithrix jacchus) is likely to replace other primate models including 
Cynomolgus (Macaca fascicularis) and rhesus monkeys (M. mulatta). Complete 
prevalence is evident in the marmoset model, an animal which can be imaged by MRI. It 
has a relapse-remitting or primary-progressive clinical course, MS-like pathology including 
axonal pathology, evidence for B-cell/antibody involvement, and the possibility of adoptive 
transfer between chimeric twins. There is not much major histocompatibility complex 
(MHC) II polymorphism of DR and DQ equivalent regions and both MBP and proteolipid 
protein (PLP) can induce disease. The EAE model is being used more and more in testing 
therapeutics [282]. Mouse models are becoming increasingly important in studying MS and 
are replacing primates because of the high cost of using the latter. Furthermore, mouse 
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genetics has been further developed than that of other species. Producing transgenic and 
gene-deficient animals often relies on using mice which are crucial for understanding the 
role of specific genes in many studies. The current concentration of systems and 
questions through one species must be kept in mind when evaluating the information that 
comes from animal studies. Two specific examples where the variables discussed have 
influenced interpretation of animal studies for MS are studies on the role of IFNγ and of 
TNFα in EAE. The strain of animals also has a major influence. EAE may be 
demyelinating or nondemyelinating, monophasic, or relapse-remitting [270] based on the 
strain of rat chosen. Specific to the strain of mouse and adjuvant chosen, the same 
encephalitogenic peptide can induce either an RRMS-like or a PPMS-like EAE [283]. 
Table 1.2: Use of selected species of animal in studies of EAE since 1950 
Decade Mouse Rat Rabbit Guinea pig Monkey 
1950-1960 0 0 0 0 0 
1960-1970 0 4 1 3 0 
1970-1980 30 111 27 140 10 
1980-1990 174 416 50 320 21 
1990-2000 775 727 52 234 32 
2000-2004 517 (147) 274 (78) 24 (69) 54 (15) 38 (10) 
 
Data are listings of numbers found in PubMed searching for Species (as per column headings) and EAE. 
The numbers in parantheses are for 2000-2004 over a 10-year period based on approximately 3.5 years already 
listed.  
When EAE first appeared in the PubMed service of the National Library of Medicine in 1962 [284], the number 
of studies employing rat and guinea pig were approximately the same until the 1990s when the mouse became more 
widely used than the guinea pig. From 2000 onwards, studies that were under the search title of “mouse + EAE” were 
greater than all other “species + EAE” results (Table). Throughout the decades, there has been a triplicate increase in 
“monkey + EAE” studies from the 1990s to this decade (projected), which translates into the possibility of increased 
primate usage in future.  
  
1.6.4.6 Interferon-γ Controversy 
As stated previously, IFNγ is the paradigmatic Th1 cytokine. Pro-inflammatory 
cytokine is responsible for inducing the expression of MHC, adhesion ligand, and co-
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stimulator ligand. Additionally, other cytokines, like TNF-α are also induced to be 
expressed. Levels of IFNγ protein and ribonucleic acid (RNA) went up in target tissue in 
many autoimmune diseases, and in the CNS in MS and EAE [285]. These levels were 
linked to the severity of disease and they fell in remission. Naturally, it was logical to 
draw a causative relationship between the IFNγ and CNS inflammatory disease. Due to 
the fact that IFNs are described as antiviral mediators and there is an assumed link 
between viral infection and MS, the IFNγ was delivered via intravenous injection to 
RRMS patients with the belief that the viral cause of disease would be for the patients’ 
advantage.  Unexpectedly, the attack rate increased during the one month of weekly 
administration, causing the study to halt in light of safety concerns [286]. Regardless of 
certain perceived shortcomings in the study design [287], it was found that IFNγ facilitated 
or even worsened MS. In another study, antibodies were given against the IFNγ-
receptor to patients with SPMS. After progression, improvement was evident which 
suggests a disease-worsening role for IFNγ in MS [288]. 
1.6.4.7 IFNγ in EAE 
Surprisingly, analogous interventions in EAE models have produced the exact 
opposite effects [285]. Some of these interventions have been more invasive than would 
be possible for clinical studies, using viral vectors [289] or directly injecting the CNS with 
antibodies. The same experimental design employed in MS has never been repeated in 
animals. Overall, it was found that completely opposite results were produced in MS 
and EAE. In MS, IFNγ makes the disease worse unlike in EAE, where IFNγ ameliorated 
the disease or prevented it from occurring. The question that emerges is whether the 
EAE model is the incorrect choice to use for MS and whether there are major 
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differences between animals and humans regarding the role of IFNγ, or something else.  
1.6.4.7.1 IFNγ & CD8 T- Cells 
That “something else” may be that EAE is inducible by CD8+ T-cells [278-280]. In 
one of these studies, anti-IFNγ antibodies were needed to prevent disease [279]. This is 
probably the only point where an IFNγ blockade has inhibited EAE, and so produced a 
great deal of interest [290]. There was a suggestion that the discrepancy between EAE 
and MS as to the effects of an IFNγ blockade may be suggestive of an artefactual 
predominance of CD4+ T-cells in EAE. However, inducing EAE with CD8+ T-cells has 
never been replicated after the initial publication and these two papers are the only ones 
that describe CD8 induced EAE. Another perspective is that the demyelinating disease 
that occurs in mice over-expressing the co-stimulator ligand B7.2/CD86 on microglia. 
CD8+ T-cells also mediate this disease [291]. These cells also produce IFNγ which causes 
adjuvant-independent encephalomyelitis, suggesting that this is more preferable to EAE 
as an animal model of inflammatory events in MS [291]. It is uncertain whether IFNγ 
blockades inhibit disease. 
1.6.4.7.2 IFNγ in Viral Encephalomyelitis 
One way to answer these questions is to determine whether IFNγ has similar 
roles in viral inflammation in the CNS. CD4+ and CD8+ T-cells are trigged as part of the 
immune response to the TMEV infection and subsequent demyelinating disease, and 
therefore, offers another system for evaluating the role of IFNγ. The cytotoxic and 
humoral immune response to viral in the CNS does not usually use IFNγ [292-293], even 
though the decreased expression of immune markers was not found in the CNS of IFNγ-
deficient, TMEV-infected mice of susceptible background. The disease occurred more 
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swiftly when IFNγ was delivered intracerebrally [292]. There was a correlation between 
motor dysfunction and axonal damage [294], and both viral persistence and neuronal 
damage were greatly increased by an IFNγ  blockade or deficiency [293]. The lack of IFNγ 
or its blockade did not inhibit the demyelination that normally occurs with a TMEV 
infection [293], suggesting that there is consistency between viral and autoimmune 
animal models. In IFNγ-deficient mice, demyelination was worse, and an IFNγ deficiency 
or blockade both overcame strain-dependent resistance to TMEV demyelination [293]. 
Neuronal damage worsened in mice that were normally susceptible to TMEV 
encephalomyelitis [293]. 
These observations also suggest another point: intra-strain variation within a 
species can have effects that are as dramatic as intra-species differences in some 
cases. This is important when interpreting findings (e.g. from EAE studies where effects 
of a similar immunization may produce varying results from no demyelination to major 
demyelination. This also depends on the mouse strain).  
1.6.4.7.3 IFNγ Expression in CNS  
1.6.4.7.3.1 Transgenic or Hypodermic 
An alternative method involves looking at results from transgenic mice. All of the 
transgenic mice with only one exception had an IFNγ over-expression in the CNS and 
used oligodendrocyte (OLG)-specific promoters, and all showed pro-inflammatory 
effects, from spontaneous demyelination and inflammation to a more severe disease 
where EAE was induced with myelin protein and adjuvant immunization [285, 295-296]. 
Transgenic models exhibit the effects of IFNγ which are different from those that occur 
after the IFNγ or IFNγR blockade, or a genetic deficiency of IFNγ. Directly injecting IFNγ 
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into the CNS using a hypodermic needle induced inflammation in rats [297-298] (mice have 
not shown the same results so far). Consequently, direct injection and transgenesis 
exhibit similar results. Only one difference exists between these experiments and those 
in which IFNγ had an immunoregulatory role where an absence of adjuvant in transgenic 
or hypodermic IFNγ models. Despite the fact that this can be easily criticized, is not as 
clear as it may initially appear. For example, transgenic mice that expressed IFNγR in 
OLG showed worsening severity of EAE as induced by myelin basic protein with CFA 
[295].  
These data which were obtained from several studies show a lot of material for 
discussion and debate. Both transgenic and hypodermic administration of IFNγ to rodent 
CNS have qualities that are also found in those of two studies in which IFNγ was marked 
in MS, which is that IFNγ was found to be pro-inflammatory. Animal experiments in which 
IFNγ was targeted or administered during EAE show an effect that is opposite and 
protective instead. IFNγ had a protective effect against virus infection and CNS damage in 
Theiler’s virus encephalomyelitis (TMEV) [292]. Two points must be emphasized which are 
that animal models are not monolithic, like MS, and the immune-regulatory effects of IFNγ 
on CNS inflammation have been seen only in animals. Therefore, depending on the 
animal model chosen for MS, one can find results that corroborate or counter the MS 
experience. Rodents model the inflammatory role of IFNγ well. However, whether EAE is 
a good model for MS is not what one should be focusing on. The question that should be 
asked is whether one can get answers by asking specific questions about certain aspects 
of MS by studying certain forms of EAE.  
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1.6.4.8 Role of Adjuvants 
The effects of IFNγ are greatly different from EAE to MS. Despite the imperfect 
correspondence, there is some ground to suspect that adjuvants (or TLR signaling, as 
in the case of viral infection) may be an important difference between the MS-like and 
MS-unlike systems. This is supported by the observation that immune-suppression in 
bacilli Calmette-Guerin (BCG, M. tuberculosis)-infected mice was overcome in the 
absence of IFNγ [299], with findings from the same and other groups showing an IFNγ-
dependent nitric oxide (NO)-mediated T-cell suppressive mechanism [300-301]. This type 
of observation is often made in CFA or pathogen-involving experimental systems. 
Simultaneously, disease-improving IFNγ was given to mice by a herpes virus vector [289], 
and IFNγ deficiency showed a protective role for this cytokine against TMEV 
encephalomyelitis in mice. Both viruses would act as TLR ligands. If a certain effect of 
bacterial PAMPs is evident (e.g. from M. tuberculosis) in directing a protective role for 
IFNγ, then incidental infections may influence the course of MS. This shows an 
interesting and probable explanation for some. 
It is interesting to note that Chlamydia pneumonia has been isolated from a very 
high number of MS cases [302]. However the evidence to connect MS with C. pneumonia 
has not been found so far.  
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1.6.5 EAE Pathology 
1.6.5.1 Demyelination - Chemical or Inflammatory  
Demyelinating pathology is also seen in animals by using myelin-specific toxins. The 
most commonly used toxins include copper chelator cuprizone [303-304], the chromatin-
disrupting agent ethidium bromide (EtBr) [305-306], and the lipid toxin 
lysolecithin/lysophosphatidylcholine (LPC) [307, 308]. These have been used to model certain 
facets of demyelinating pathology, their advantage since local administration or intrinsic 
characteristics allow prediction of the site of effect, unlike in EAE where lesion occurrence 
is always uncertain. Cuprizone and EtBr have been used to study remyelination and these 
studies have furthered our understanding of oligodendrocyte precursor cells and their 
dynamics [304, 306]. It can be said that toxin-induced demyelination is not a reliable model for 
MS. These models are not used with an established causal relationship between a toxin 
and the disease but to understand the mechanism underlying this. Therefore, they further 
our understanding of demyelination and remyelination. There is a downstream, 
inflammatory component to toxin-induced demyelination and study of cellular and 
cytokine/chemokine responses have contributed to a better understanding of injury-reactive 
inflammation in the CNS, which may occur in MS [308-309]. Another method that can be used 
is to transgenically promote demyelination by over-expressing the DM-20 myelin proteolipid 
[310]. This produced a mouse (the ND4 trangenic) which myelinates normally but develops 
spontaneous demyelination with attendant immune sequelae as it ages [311]. This would 
seem to produce a useful model for Type IV MS pathology [6]. 
1.6.5.2 Different Effects in Humans and Mice  
Generally, one can learn from parallel situations in which the players are different 
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but the same principles apply. If IFNγ-induced, NO-mediated immune-regulation turns 
out not to be a main feature of immune-regulation in humans, then one can expect that 
another cytokine-driven system will work in its place. Whether human 
macrophages/microglia uses an equivalent source of NO as their murine counterparts 
may be one critical species-specific difference [312]. Reports of elevated iNOS expression 
and NO levels in MS tissue are interpreted as showing a cytopathic effect for NO [313], but 
it should be remembered that the same correlations were seen in EAE.  A number of 
contradictory inhibitor studies along with unexpected findings for iNOS-deficient mice 
moved our thinking towards the possibility of a neuroprotective role for NO [312]. Some 
interest has been shown in IL17 as a potential alternative inflammatory cytokine to IFNγ in 
facilitating inflammatory responses in mice [314]. We are familiar with other species-
specific differences, such as that there is no IL8 in mice and the preferential role of GM-
CSF over IL3 in hematopoietic stem cell growth in humans. Therefore, we should not 
expect exact trans-species homology in the mechanism of effect rather look for the 
similar regulatory systems.  
1.6.5.3 Effects of Interventions 
With animal models, one can tell whether a reagent directly accesses the CNS. 
In MS, however, this is not possible and too often, the only thing we know for certain is 
that the drug or reagent accesses the periphery. The increased attack rate in the 
intravenous IFNγ study was suggested to reflect intra-CNS action of IFNγ because of 
the likelihood of a blood-brain barrier in these patients [286]. It is also possible that the 
cytokine and the anti-receptor antibody in a later study acted purely on the peripheral 
immune response. Administering IFNγ to mice or rats using the viral infection of 
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ependymal cells [289], or of cytokine or antibodies using the hypodermic route [297-298, 315], 
places IFNγ or antibodies directly in the CNS, and it is possible that the discrepant 
results between animals and MS patients reflect that difference in site of action. This 
may be due to aid in explaining the discrepancy between effects of TNF-α-targeting 
reagents in EAE versus in MS [316]. EAE was inhibited by anti-TNF-α but drugs that were 
based on similar principles did not ameliorate MS.  
It would be crucial to know whether there was differential access to the CNS in 
MS patients versus in animals. The fact that some patients showed worsening 
symptoms is probably due to the differential effects of TNF-α acting through either of the 
two receptors for this cytokine, one of which signals for oligodendrocyte precursor cell 
survival [317]. The same drugs are effective against rheumatoid arthritis, but some 
patients exhibited neurological problems [318]. It would be difficult to explain how this 
may occur if the anti-TNF-α drugs did not access the CNS, although these questions 
remain unanswered. 
1.6.6 Summary 
As there is no specific pathology which defines MS, there is no single animal model 
for MS. Choice of animal species is critical and it may be important to maintain 
studies of less-popular models to maintain a broad perspective. The most commonly 
used animal model of EAE demonstrates differences in immune regulation and CNS 
pathology from that of MS. It is still a useful model for autoimmune inflammation 
(Table 1). Viral encephalomyelitis models exhibit some of the same immune-
regulatory distinctions as EAE, possibly due to being focused on mice. Transgenic 
models permit the study of specific aspects of disease and its induction even though 
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they are inevitably mouse models. Toxin-induced demyelination has been useful in 
examining regenerative processes, with the obvious disclaimer that there is little 
evidence supporting a role for toxins in MS. Finally, one has to choose whatever 
model is important for the question one wishes to address. The greatest risk is to 
over-interpret results from any one model as being representative of what is a 
globally heterogeneous disease. 
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2.0 HYPOTHESIS 
We hypothesize that the phase 2 enzyme inducers can improve EAE. 
 The phase 2 enzymes like glutathione peroxidase with the help of glutathione 
(GSH) can convert reactive oxygen intermediates like hydrogen peroxide into water and 
oxygen molecule. The oxidative stress has been attributed in the mechanism of damage 
in EAE and MS. [216, 233] Therefore, those chemicals that increase the phase 2 enzyme 
can benefit EAE through antioxidation. [225, 226]   
2.1 EAE - Animal Model 
At the turn of the century, EAE was identified as an "allergic" side effect seen in 
those individuals who had been administered the Pasteur rabies vaccine. This vaccine 
is comprised of the fixed rabies virus that had been grown in rabbit brain tissue. Acute 
disseminated encephalomyelitis [ADEM] which is a monophasic paralytic illness was 
seen in about 0.1% of vaccine recipients [166]. Perivascular mononuclear cell infiltrate 
and focal areas of demyelination in CNS tissue from these individuals was also 
observed. ADEM was not a result of rabies vaccine. It was due to CNS tissue that was 
used to develop rabies vaccine. In 1947, introducing adjuvants as well as homologous 
brain tissue led to the first reproducible induction of "allergic" encephalomyelitis in 
experimental animals [166]. Therefore, the murine EAE was identified as a model for 
demyelinating disease of CNS. To date, EAE has been successfully induced in many 
animal species, such as mice and rats. 
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3.0 MATERIAL AND METHOD 
3.1 Experimental Model 
24 Lewis rats between the ages of 10-12 weeks were purchased. The animals 
were housed at standard condition of a 12-hour light/dark cycle and fed in the animal 
facility. The animals were inoculated with 100 µg of Myelin Basic Protein (MBP) with 
Complete Freund’s Adjuvant (CFA) at their tail base.  
3.1.1 Experimental Technique 
All the rats were inoculated with MBP + adjuvant (CFA) at the beginning of the 
experiment in a batch of 3 or 4 rats a day so that each one of them can be sacrificed 
exactly after the 28th day of the inoculation.    
The animals were separated into two groups of 12 each after inoculation. The 1st 
group was fed their normal diet chow (without added BHA) for all of the 28 days from 
the induction of EAE. The 2nd group consumed a diet chow containing a 7.5 g/kg 
concentration of BHA from induction of EAE until the 28th day. 
The animals underwent clinical evaluation (behavioral examination) by two 
people that were blinded to the experiment, in each animal group, twice daily for 28 
days. The grading system were ranging from 0 (no overt symptoms) to 3 (hind limb 
paralysis). On the 29th day of post-induction of EAE, the animals were anesthetized 
with halothane inhalation. The blood samples in EDTA were collected by cardiac 
puncture. Then the animals were sacrificed by the perfusion of saline through the left 
cardiac ventricle. The animals were dissected to obtain the spinal cord and the brain. 
These tissues were fixed in 10% formaldehyde.  
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3.1.2 Clinical Scoring (Grades of Symptoms) 
The tail, forelimb, and hind limb of the animals were examined for weakness as 
described in Pender [319] in a double blinded fashion. The clinical scoring is as follows: 
0 No overt symptoms  
  0.5 Tail weakness only 
  1 Tail paralysis 
  1.5 Tail paralysis with some hind limb weakness  
  2 Hind limb weakness 
  3 Hind limb paralysis 
 All the animals were examined twice daily (12 hourly) and the grades were 
recorded from the day of induction until the 28th day. 
3.1.3 Histological Studies 
The multiple 10 mm sections of the formalin fixed spinal cord and brain were 
taken. The spinal cord samples were from cervical, thoracic and lumbosacral regions. 
These tissue samples were processed in an automated tissue processor for 
dehydration. The processed tissues (dehydrated) were embedded in paraffin blocks. 
Then the serial sections of the brain and spinal cords were made using microtome. 
These sections were taken on the slides that are coated with tissue fixative and 
rehydrated to stain with water soluble hematoxylin and eosin. The sections are first 
stained by hematoxylin for 4 minutes. Then 0.3% acid alcohol is used for differentiation 
to the point that after blueing up, the background is colorless. This is followed by 
staining with eosin for 2 minutes. Over staining by eosin is removed by washing in 
running water. Then the sections are dehydrated and cleared followed by mounting with 
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a cover slip.    
The 10 sections of the spinal cord (of cervical, thoracic & lumbosacral segments) 
and the brain were examined for the presence or absence of inflammation. The 
presence of mononuclear infiltrate around the vessels and/or parenchymal mononuclear 
infiltration is considered as presence (positive) of inflammation. These findings were 
documented in both the groups of rats as positive and negative for inflammation.  
3.1.4 RBC Glutathione (GSH) Estimation [320] 
 The whole blood samples of all the animals that were collected in an EDTA 
container and stored in 4º C are used for the estimation of RBC glutathione (GSH). 
 To prepare the samples for GSH estimation, the equal volumes of the whole 
blood and 30% Tri-chloro-acetic acid (TCA) containing 2mM of Ethylene diamine tetra-
acetic acid (EDTA) are mixed in a test tube to deproteinize it. The final concentration of 
TCA becomes 15% which is essential to preserve the GSH. This mixture is centrifuged 
at 15000G for 5 minutes at 4 ºC. The acidic supernatant is removed in a separate test 
tube and stored at –80ºC until it is used for GSH estimation.     
 The stock solution of reagents is made by adding 0.5M potassium phosphate in 
1mM of EDTA to make a buffer with pH 7. Then 2 mg of 1-Chloro-2,4-dinitrobenzene 
(CDNB)  is mixed in 1 ml of ethanol and is placed in water bath at 37 ºC. Finally, the 
500U of enzyme Glutathione-S-transferase (GST) is dissolved in 1 ml of 0.01 M of 
phosphate buffer (PBS). 
 The frozen acidic supernatant sample is thawed. The 25 μL of samples and the 
standards are placed in separately labeled microcuvettes. Then 825 μL of potassium 
phosphate is added in each microcuvettes followed by 10 μL of CDNB and GST each. 
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The CDNB is well shaken before adding it into microcuvettes. The GSH-CDNB 
conjugate is catalyzed by GST enzyme. The reaction takes 5 minutes to reach the end 
point. The absorbance of the mixture is measured by a spectrophotometer at 340 nm. 
The GSH is estimated by using the Beer and Lambert Equation; C = A/E. (C = 
Concentration; A = Absorbance; E = Extinction coefficient, which is 9,600 M-1 cm –1) 
 
Experiment Strategies 
 
                                               
 
 
                                                                        
 
 
                                                             
 
 
 
 
 
 
Fig. 3.1.. : Experiment Strategy 
Inoculated subcutaneously at tail 
EAE induced animals are fed 
with Non-BHA/BHA feeds
24 Lewis Rats 10-12 weeks old 
With 100 µg of Myelin Basic Protein 
(MBP) + Complete Freund’s Adjuvant 
(CFA) 
Normal Chow  
Chow feed 
soaked with 
BHA 7.5 g/kg 
BHA Chow 
Daily symptoms 
were graded as 
per Pender et al 
[243] 
On 29th day of EAE induction, all the 
animals were anesthetized by halothane 
inhalation. The EDTA blood samples were 
collected from all the rats. Then the rats 
were sacrificed by saline infusion 
followed by dissection to obtain entire 
brain and spinal cord. 
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4.0 RESULTS  
4.1 Clinical Scoring 
 The following tables show the clinical scoring of non-BHA and BHA groups.  
Table 4.1.1: non-BHA fed EAE – Grades of symptoms 
EAE IN LEWIS RATS 
non-BHA fed - Grades of Symptoms 
Dates / 
Rats H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
Feb. 22, '06 0‐In  0‐In  0‐In  0  0  0  0  0  0  0  0  0 
Feb. 23, '06 0  0  0  0‐In  0‐In  0‐In  0‐In  0  0  0  0  0 
Feb. 24, '06 0  0  0  0  0  0  0  0‐In  0‐In  0‐In  0‐In  0 
Feb. 25, '06 0  0  0  0  0  0  0  0  0  0  0  0‐In 
Feb. 26, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Feb. 27, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Feb. 28, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 1, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 2, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 3, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 4, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 5, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 6, '06 0.5  0  0.5  0.5  0  0  0  0.5  0.5  0.5  0  0 
Mar. 7, '06 0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0  0.5 
Mar. 8, '06 1  0.5  0.5  1  0.5  1  0.5  1  1  1  0.5  0.5 
Mar. 9, '06 1  0.5  1  1  1  1  1  1  1  1  0.5  1 
Mar. 10, '06 1  1  1  3  1  2  1  2  1  2  1  1 
Mar. 11, '06 2  1  1  2  1  3  1  3  2  3  1  1 
Mar. 12, '06 1  1  2  1.5  2  3  1.5  3  1  3  1.5  2 
Mar. 13, '06 1  1  1  1.5  1  3  2  3  1  3  2  1.5 
Mar. 14, '06 1  2  1  1  1  2  2  2  1  3  1.5  1.5 
Mar. 15, '06 1  1  1  1  1  1  1  1  1  2  1.5  1 
Mar. 16, '06 1  1  1  1  1  1  1  1  1  1  1  1 
Mar. 17, '06 1  1  1  1  1  1  1  1  1  1  1  1 
Mar. 18, '06 1  1  1  1  1  1  1  1  1  1  1  0.5 
Mar. 19, '06 0.5  0.5  1  0.5  1  1  0  1  1  1  0.5  0.5 
Mar. 20, '06 0  0.5  0  0.5  1  1  0  0.5  1  1  0.5  0.5 
Mar. 21, '06 0  0  0  0  0  0.5  0  0  1  1  0  0 
Mar. 22, '06 S  S  S  0  0  0  0  0  0  0  0  0 
Mar. 23, '06          S  S  S  S  0  0  0  0  0 
Mar. 24, '06                      S  S  S  S  0 
Mar. 25, '06                                  S 
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Table 4.1.2: BHA fed EAE – Grades of symptoms 
EAE IN LEWIS RATS 
BHA fed - Grades of Symptoms 
Dates / 
Rats H13 H14 H15 H16 H17 H18 H19 H20 H21 H22 H23 H24
Feb. 22, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Feb. 23, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Feb. 24, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Feb. 25, '06 0‐In  0‐In  0‐In  0  0  0  0  0  0  0  0  0 
Feb. 26, '06 0  0  0  0‐In  0‐In  0‐In  0‐In  0  0  0  0  0 
Feb. 27, '06 0  0  0  0  0  0  0  0‐In  0‐In  0‐In  0  0 
Feb. 28, '06 0  0  0  0  0  0  0  0  0  0  0‐In  0‐In 
Mar. 1, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 2, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 3, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 4, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 5, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 6, '06 0  0  0  0  0  0  0  0  0  0  0  0 
Mar. 7, '06 0.5  0  0  0  0  0  0  0  0  0  0  0 
Mar. 8, '06 0.5  0.5  0.5  0.5  0.5  0  0.5  0  0.5  0.5  0  0.5 
Mar. 9, '06 1  1  1  1  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5 
Mar. 10, '06 1  1  1  1  1  1  1  0.5  0.5  1  1  1 
Mar. 11, '06 2  3  3  3  1  1  1  0.5  1  1  1  1 
Mar. 12, '06 2  3  2  2  1.5  1  1  1  1  1  1  3 
Mar. 13, '06 3  3  3  3  3  2  2  1  1  3  3  3 
Mar. 14, '06 3  2  3  2  3  2  2  1  1  3  3  2 
Mar. 15, '06 2  1.5  2  1.5  2  1.5  1.5  1  1  2  2  1.5 
Mar. 16, '06 1  1.5  1.5  1.5  1  1.5  1.5  1  1  1.5  1.5  1.5 
Mar. 17, '06 1  1  1  1  1  1  1  1  1  1  1  1 
Mar. 18, '06 1  1  1  1  1  1  1  1  1  1  1  1 
Mar. 19, '06 1  1  1  1  1  1  1  1  1  1  1  1 
Mar. 20, '06 0.5  1  1  1  1  1  1  0.5  1  1  1  1 
Mar. 21, '06 0.5  0.5  1  0.5  1  1  0.5  0.5  0.5  1  1  1 
Mar. 22, '06 0  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5  1  0.5  1 
Mar. 23, '06 0  0  0  0  0  0.5  0  0  0.5  0.5  0.5  1 
Mar. 24, '06 0  0  0  0  0  0  0  0  0.5  0.5  0  0.5 
Mar. 25, '06 S  S  S  0  0  0  0  0  0  0  0  0.5 
Mar. 26, '06          S  S  S  S  0  0  0  0  0 
Mar. 27, '06                      S  S  S  0  0 
Mar. 28, '06                               S  S 
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Legends 
In - Induction of EAE by MBP + adjuvant 
S - Rats were sacrificed by perfusing saline under halothane 
 
Table 4.1.3: BHA and non-BHA fed EAE – Clinical symptoms 
Clinical Scoring in non-BHA & BHA fed Animals  
Symptoms Tail 
paralysis 
Hind limb 
weakness 
Hind limb 
paralysis Chow fed 
non-BHA 0 8 4 
BHA 2 2 8 
 
4.1.1 Statistical Analysis – Mean of Grades of Symptoms in Rats 
 
Fig. 4.1: The mean of grades of symptoms in BHA and non-BHA fed Lewis rats, 12 animals in each group. The dark 
black lines in box plot indicate the mean in each group. The x-axis indicates the two groups of animals; BHA and non-
BHA fed rat. The y-axis is mean of grades of symptoms of each animal. The mean in BHA fed animals is 0.6622 and 
that of non-BHA is 0.5818. The range of grades of symptoms in BHA is lower than that of non-BHA. The independent 
t-test shows that there is no statistically significant difference between these two groups because the p value is 0.170, 
which is more than 0.05   
BHA and non-fed Lewis rats 
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4.1.2 Comparative Graphs of Grades of Symptoms of Each Rat (H1 to H24) 
The grades of symptoms are compared in a pair of two animals in each figure 
below. The 24 animals are labeled as H1, H2…H24. The H1 to H12 are non-BHA group 
of Lewis rats and H13 to H24 are BHA fed group of Lewis rats. Statistically there is no 
significant difference between the groups as the p value is 0.17 which is more than 
0.05. 
 
Each Lewis rat is inoculated to induce EAE on a particular date then examined daily for 
grades of symptoms until 28 days later. Each animal is sacrificed on the following day. 
 
The x – axis is the dates starting from inoculation for induction of EAE in each Lewis rat 
until 28 days. 
 
The y – axis (values) are grades of symptoms. 
 
The comparative analysis of fig. 4.2(a) to fig. 4.2(l) is given at the end of the graphs.   
 
 
   
 
 Fig. 4.2(d) Fig. 4.2(c) 
Fig. 4.2(a) Fig. 4.2(b) 
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Fig. 4.2(e) Fig. 4.2(f) 
Fig. 4.2(g) Fig. 4.2(h) 
Fig. 4.2(i) Fig. 4.2(j) 
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Non-BHA:  Acute attack 
No symptoms – 10 to 13 days 
                 Tail weakness – 2 to 3 days 
  Tail paralysis – 2 to 4 days 
 Tail paralysis with some hind limb weakness – 1 day (2 cases) 
  Hind limb weakness – 1 day (11 cases) 
  Hind limb paralysis – 1 to 4 days (4 cases) 
 
  Remission 
Hind limb weakness – 1 day (4 cases) 
Tail paralysis with some hind limb weakness – 2 days (3 cases) 
Tail paralysis – 3 to 10 days 
Tail weakness – 1 to 3 days (7 cases) 
No symptoms – 1 to 4 days 
 
BHA:   Acute attack 
No symptoms – 8 to 11 days 
                 Tail weakness – 1 to 2 days 
Tail paralysis – 2 to 3 days (except 2 cases, that had only this symptoms for 8 and 
10 days each before remission as tail weakness started) 
 Tail paralysis with some hind limb weakness – 1 day (1 case) 
  Hind limb weakness – 2 days (3 cases) 
Hind limb paralysis – 1 to 3 days (8 cases; 7 cases had no hind limb weakness) 
 
  Remission 
Hind limb weakness – 1 day (8 out of 10 cases) 
Tail paralysis with some hind limb weakness – 1 to 2 days (8 out of 10 cases) 
Tail paralysis – 4 to 7 days (8 out of 10 cases) 
Tail weakness – 1 to 4 days 
No symptoms – 2 to 4 days 
 
There are variations in symptoms of acute attacks and remission in non-BHA and BHA 
groups. However these differences are statistically insignificant as the p value is 0.17. 
Fig. 4.2(k) Fig. 4.2(l) 
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4.2 Histology Screening 
 The light microscopy examination of the serial sections of the spinal cords from 
cervical, thoracic, lumbosacral regions including sections of cerebrum, cerebellum, and 
brain stem were undertaken. The predominant histological findings were mononuclear 
cell infiltration composed of lymphocytes, macrophages, and microglia. These infiltrates 
were arranged generally like perivascular cuffing (around the blood vessels) with few 
focal collections and sparsely scattered infiltration. Group-1 (non-BHA fed) showed the 
typical histological findings in all except in three (H6, H9, and H11) where there has 
been mainly focal collections and scattered mononuclear infiltrations with mild 
perivascular cuffing. In group-2 (BHA fed), there have been no findings that suggest any 
inflammatory response. The results are presented in the following table 4.2.1 
Table 4.2.1: Histology changes in non-BHA fed and BHA-fed EAE animals 
EAE IN LEWIS RATS 
non-BHA fed - Histology - I 
Rats H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
Histology P  P  P  P  P  MP  P  P  MP  P  MP  P 
 
EAE IN LEWIS RATS 
BHA fed - Histology - II 
Rats H13 H14 H15 H16 H17 H18 H19 H20 H21 H22 H23 H24
Histology N  N  N  N  N  N  N  N  N  N  N  N 
 
Legends 
P - Perivascular infiltration by mononuclear cells 
N - No perivascular infiltration by mononuclear cells 
MP - Mild perivascular infiltration by mononuclear cells
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The histology of the sections of the spinal cord and the brain were consistent with 
the pathological changes of perivascular mononuclear cuffing with focal collections and 
scattered mononuclear infiltrates. As anticipated, not all the sections of the brain and/or 
the spinal cord of non-BHA revealed inflammation. There have also been sections that 
show perivascular cuffing and normal blood vessels indicating the patchy nature of 
inflammation in the brain and the spinal cord in acute EAE. This acute EAE leads to 
relapsing remitting EAE or chronic EAE where the patchy nature of pathology turns to 
extensive damage manifested by an increasing degree of neurological deficit. The 
histology slides of non-BHA and BHA fed animal are presented below in fig. 4.3 (non-
BHA) and 4.4 (BHA). 
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Fig. 4.3: Histology of non-BHA fed animals (group 1); H1 to H12 
     SC = Spinal cord and Br = Brain 
 
                   
 
 
 
                   
    
 
 
                   
 
 
 
 
 
 
 
H1- SC – perivascular and 
scattered parenchymal infiltrate 
H1- SC – perivascular infiltrate 
H1- Br – mild perivascular infiltrate H1- Br – perivascular infiltrate 
H2- SC – mild perivascular 
infiltrate 
H2- SC – mild perivascular and 
scattered parenchymal infiltrate 
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H3- Br – parencymal infiltrate 
 
H3- SC – perivascular and 
scattered parenchymal infiltrate 
H2- Br – mild perivascular infiltrate 
 
H2- Br – perivascular infiltrate 
 
H4- SC – perivascular and subpial 
infiltrate 
H4- SC – perivascular and 
scattered parenchymal infiltrate 
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H4- Br – perivascular and 
scattered parenchymal infiltrate 
H4- Br – perivascular infiltrate 
 
H5- SC – mild perivascular and 
scattered parenchymal infiltrate 
H5- SC – mild perivascular 
infiltrate 
H5- Br – perivascular and 
parenchymal infiltrate 
H5- Br – perivascular and 
scattered parenchymal infiltrate 
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H6- SC – mild perivascular 
infiltrate 
H6- Br – parenchymal infiltrate 
 
H7- SC – mild parenchymal 
infiltrate 
H7- SC – mild parivascular 
infiltrate 
H7- Br – perivascular infiltrate 
 
H7- Br – perivascular infiltrate 
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H8- SC – mild parenchymal 
infiltrate 
H8- SC – mild parenchymal 
infiltrate 
H8- Br – mild perivascular infiltrate 
 
H8- Br – perivascular infiltrate 
 
H9- SC – mild parenchymal infiltrate 
 
H9- Br – perivascular infiltrate 
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H10- SC – mild perivascular infiltrate 
 
H10- Br – perivascular infiltrate 
 
H11- SC – perivascular infiltrate 
 
H11- Br – mild perivascular infiltrate 
 
H12- SC – perivascular infiltrate 
 
H12- Br – perivascular infiltrate 
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Fig. 4.4: Histology of BHA fed animals (group 2); H13 to H24 
               SC = Spinal cord and Br = Brain 
 
               
 
 
 
 
               
 
 
 
 
                 
 
 
 
 
H13- SC – no perivascular infiltrate H13- Br – no perivascular infiltrate 
H14- SC – no perivascular infiltrate H14- Br – no perivascular infiltrate 
H15- SC – no perivascular infiltrate H15- Br – no perivascular infiltrate 
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H16- SC – no perivascular infiltrate 
H17- SC – no perivascular infiltrate 
H18- SC – no perivascular infiltrate H18- Br – no perivascular infiltrate 
H17- Br – no perivascular infiltrate 
H16- Br – no perivascular infiltrate 
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H19- SC – no perivascular infiltrate 
H20- SC – no perivascular infiltrate 
H21- SC – no perivascular infiltrate H21- Br – no perivascular infiltrate 
H20- Br – no perivascular infiltrate 
H19- Br – no perivascular infiltrate 
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H24- SC – no perivascular infiltrate 
H22- SC – no perivascular infiltrate 
H23- SC – no perivascular infiltrate 
H24- Br – no perivascular infiltrate 
H23- Br – no perivascular infiltrate 
H22- Br – no perivascular infiltrate 
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4.3 RBC Glutathione (GSH) Estimation 
Table 4.3: Levels of Glutathione in non-BHA and BHA fed EAE animals 
EAE IN LEWIS RATS 
non-BHA fed - Glutathione - I 
Rats H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
Glutathione 11.5  13  12  12  13  14  12.5  11  13.5 14.5  13.5  13 
 
EAE IN LEWIS RATS 
BHA fed - Glutathione - II 
Rats H13 H14 H15 H16 H17 H18 H19 H20 H21 H22 H23 H24
Glutathione 24.5  27  28.5  26  26  30  27.5  29  23.5  29.5  25  26 
 
4.3.1 Statistical Analysis – GSH levels in BHA and non-BHA fed rats 
 
Fig. 4.5: The GSH levels have been shown in BHA fed and non-BHA fed Lewis rats, 12 animals in each 
group. The x-axis corresponds to two groups of animal studied; BHA and non-BHA fed rats. The y–axis is 
the level of GSH in each animal. The dark black lines in box plot indicate the mean in each group. The 
mean in BHA fed animals is 26.88 μMoles/ml RBCs and that of non-BHA is 12.79 μMoles/ml RBCs. The 
range of GSH levels in non-BHA is 11 to 14 and that of BHA is 23.5 to 30. The independent t-test shows 
that there is statistically significant difference between these two groups because the p value is 0.000 
which is less than 0.05.   
BHA and non-fed Lewis rats 
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5.0 DISCUSSION 
The behavioral study for clinical scoring has been performed as stated earlier in 
a double-blinded fashion to avoid bias. The findings ranged from no changes to hind 
limb paralysis at various days after induction until the 28th day. The rats were sacrificed 
on the 29th day of the induction of EAE. In the first group of non-BHA fed animals, all 
eventually showed the clinical symptoms. However, all recovered from it by showing no 
symptoms of weakness or paralysis by the 28th day. The histology of the non-BHA fed 
animals revealed an inflammatory disease (EAE) in the spinal cord and the brain of 
each animal.  
 In the 2nd group of BHA-fed animals, there has been no noticeable difference in 
symptoms from the 1st non-BHA fed group of animals. However, the histology of the 
BHA fed animals did not show any evidence of inflammatory disease (EAE). An 
inflammatory reaction has been attributed to the clinical symptoms ranging from 
weakness to paralysis [225, 226, 321]. The statistical analysis was performed using the 
means of grades of each animal (sum of grades of each animal/28 days) and compared 
with non-BHA and BHA groups of animal. The independent t-test shows that there is no 
statistically significant difference between these two groups of animals as the p value 
has been 0.17. These similar clinical presentations are different from earlier studies [226], 
where the BHA fed animals show minimal to no symptoms [226]. Even though 
histologically, there has been a clear difference in the inflammatory process in this 
study. BHA fed animals were free of inflammation as noticed in earlier studies where the 
use of BHA has improved EAE [225, 226]. How does one explain this apparent 
contradiction in clinical symptoms of all animals showing acute EAE followed by 
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remission and the histology where BHA fed animals were free from inflammation 
whereas non-BHA fed animals have revealed consistent features of inflammation in 
multiple sections of the brain and the spinal cord? The beneficial effects of BHA has 
been shown in acute EAE [226], where the animals were fed with a BHA and a non-BHA 
diet in both the groups of Lewis rats that were administered two weeks prior to the 
induction of EAE [226]. Therefore, the increased phase 2 enzyme induction prior to the 
acute EAE has most likely prevented oxidative stress before it actually caused 
inflammation. So, there has been no or minimal clinical symptoms. However, in this 
study, the animals were fed with BHA starting from the day of the inoculation of the 
animals for EAE induction. That is probably why the oxidative stress has caused clinical 
symptoms following the inflammation of the brain and the spinal cord. All the animals 
reached the remission clinically but the BHA fed animals could recover completely from 
the inflammatory process in contrast to the non-BHA fed animals due to the sufficient 
phase 2 enzyme that has been generated by the BHA. These findings give evidence in 
support of the beneficial effects of the phase 2 enzyme inducers in EAE [225, 226]. The 
histological findings have been complimented and confirmed by the raised glutathione 
(GSH) level in the BHA fed animals [226], thereby confirming the antioxidative role of 
phase 2 enzyme inducers like BHA [225-226]. The statistical test was performed on the 
level of GSH in each animal. The independent t-test reveals that there is a significant 
difference in the levels of non-BHA and BHA fed animal where the p value is 0.00. This 
also reiterates again that EAE can be improved by antioxidants [217-232] and thereby have 
potential use in the management of MS. Atorvastatin has been found promising in EAE 
models [162] and in-vitro human study has been found promising [163]. The analytical 
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explanation of the experiment can be summarized in the following. However, nothing 
excludes the extensive investigation needed to confirm these findings to know the role 
of various antioxidants in EAE and MS. 
5.1 Analysis of Data 
The clinical scoring (behavioral studies) of the Lewis rat throughout the 28 day 
duration show that all the induced EAE rats exhibited the same patterns of symptoms of 
weaknesses, partial and complete paralysis of the limbs before remission of the 
symptoms corresponding with the remission of the acute EAE.  
However, the histological observations were different. The rats (group 1) that had 
consumed a normal (not containing BHA) diet exhibited variable grades of perivascular 
mononuclear cell infiltration. The rats that were on a BHA-containing diet exhibited no 
perivascular infiltration.    
Correlation of the histological and the clinical findings show that all the rats had 
an acute EAE that ended with remission. Those rats which were on a BHA diet did show 
pathological recovery from the disease. 
The RBC glutathione levels have shown to be correlating with the histological 
findings of pathological recovery through antioxidant activity. Thereby, group 1 has 
shown no increased glutathione, however, group 2 reveals increased glutathione levels, 
confirming our inference that the ameliorating effects of BHA in diet is due to induction 
of phase 2 enzyme (antioxidant role).   
The earlier studies demonstrated the preventive potential of the phase 2 enzyme 
inducers (antioxidants), BHA. [252-253] But this study is suggestive of a possible 
pathological recovery by phase 2 enzyme inducers (BHA).  
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It is highly possible that phase 2 enzyme inducers have double potentials: 
preventive (if used well before the disease induction) and therapeutic if used during the 
disease or at the onset of the disease. 
5.2 Conclusions 
1. The phase 2 enzyme inducer (BHA) has been found to cause anti-oxidation in 
the brain and the spinal cord tissues of the EAE model. 
 
2. The phase 2 enzyme inducer (BHA) brings about pathological recovery in 
acute EAE.  
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